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ABSTRACT
Although conventional therapies for metastatic cancers have made significant progress in recent
years, they are relatively nonspecific and have many deleterious side-effects. Recently, novel
therapies, including adoptive cellular immune therapies have had sporadic, but spectacular
success in cancers such as malignant melanoma and renal cell carcinoma: tumors in which an
immune response has been demonstrated. However, other physiological mechanisms, such as
blood coagulation inhibit the immune response against cancers. Our previous work has shown
that one of these coagulation proteins, soluble fibrin (sFn), inhibits unstimulated and activated
lymphocyte adherence to tumor cells by blocking leukocyte integrin (CD11a/CD18) binding to
tumor cell CD54, suggesting that sFn is an immunosuppressive agent in cancer. Since these
receptors are also involved in lymphocyte/endothelial cell adherence and diapedesis (a necessary
step in the immune response to cancer), it was hypothesized that sFn inhibits these functions, and
that blockade of this inhibition using specific peptides would restore these immune responses.
Fluorescently labeled lymphocytes and Interleukin-2 activated lymphocytes (LAK cells) were
incubated with sFn (or its components; fibrinogen, Gly-Pro-Arg-Pro, or thrombin) in the presence
or absence of specific blocking peptides. Lymphocyte and LAK cell adherence to endothelial cell
monolayers was measured by perfusion at physiological shear rates in a microscope-mounted
closed perfusion chamber, followed by image analysis using Image Pro Plus software. Diapedesis
was measured by detection of fluorescence in 24-well microplates following immune cell
incubation (18 h) with endothelial cell monolayers grown in transwells. SFn inhibited
lymphocyte (54.1 + 11.3 %) and LAK cell (43.9 + 4.4 %) adherence to sFn pretreated endothelial
cells, and intermediate values were obtained from sFn pre-treatment of only one cell type.
Adherence was restored by peptide mediated blockade of sFn/CD54 binding, but not by CD11b
blocking peptides. Diapedesis was also inhibited by sFn (lymphocyte 29.6 + 7.7 %; LAK 12.2 +
iii

4.9 %) and restoration was observed using blocking peptides. These results confirm the stated
hypotheses, and if physiologically relevant, suggest that sFn is an etiological agent in tumor
growth and metastasis, and that blockade using fibrin specific peptides may enhance the
effectiveness of adoptive immunotherapies.
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CHAPTER 1: LITERATURE REVIEW AND INTRODUCTION
1. 1 Introduction
Conventional treatments for cancer primarily include “broad spectrum” approaches such as
chemotherapy, radiotherapy and invasive surgery. By contrast, the ability of the humoral, innate,
and cellular immune responses to specifically target and treat cancer has attracted greater research
and clinical interest in recent years. To this end, the field of immunotherapy in cancer has
developed a number of therapeutic strategies in the treatment of cancer, including antibody and
cytokine based treatments, combined chemotherapy and immunotherapy, and adoptive
immunotherapy. Adoptive immunotherapy was pioneered by Stephen Rosenberg and others in
the 1980’s, and with various modifications and improvements, has resulted in a small but
tantalizingly significant response in some melanoma and renal cell carcinoma patients, as
evidenced by a recent Science paper (Morgan, 2006). However, the mechanisms involved in
leukocyte and activated or modified leukocyte homing and specific tumoricidal responses to
cancers is still not fully understood, in part due to the multi-disciplinary interactions which are
highly probable in such therapies. These mechanisms necessarily involve leukocyte interactions
with other molecular and cellular components of the blood, vascular endothelium, tissues and
cancer cells. For example, our laboratory’s previous work has clearly shown that one of the end
products of blood coagulation, soluble fibrin (which is present in elevated levels in many cancer
patients; Iverson, 1995), significantly inhibits leukocyte adherence and killing of cancer cells in
vitro, and enhances experimental metastasis (Biggerstaff, 2006; 2007, 1999). Furthermore, the
cell surface molecules which mediate this inhibition (leukocyte integrin CD11b/CD18 and its
receptor CD54) are also highly important in leukocyte adherence and diapedesis across vascular
endothelium. In bringing the subjects of immunotherapy and blood coagulation into cancer
biology, we therefore hypothesized that soluble fibrin also inhibits unstimulated and activated
1

leukocyte adherence and diapedesis. It was further hypothesized that blockade of soluble fibrin
binding to these receptors, using specific peptides (our lab has previously demonstrated peptide
mediated restoration of leukocyte adherence to tumor cells; Biggerstaff, 2006), would restore the
ability of leukocytes to adhere to and migrate across endothelial cell (EC) monolayers.
Confirmation of this hypothesis would suggest that peptide therapies may be important as
adjuvants to adoptive immunotherapies in the treatment of cancer.

The following sections describe work in the areas of cancer biology, cancer immunology, and
fibrin biology which have led to the generation of the primary hypotheses for this project.

1. 2 Cancer
1. 2. 1 Epidemiology of Cancer
Cancer is the second leading cause of death in the United States, with more than one million
Americans diagnosed with the disease each year, with this number likely to increase as the
population increases. A recent report released by the nation's leading cancer organization finds
that although Americans' risk of dying from cancer continues to drop, maintaining a trend that
began in the early 1990s, the rate of new cancer development remains stable (Howe, 2003).

Localized cancer, or stage I of disease, is when tumor cells begin to exhibit invasion and
disruption of local tissues to form a primary lesion. Tumor cells then invade the local lymphatic
system and spread to the regional (stage II) or extended regional (stage III) draining lymph nodes
as secondary tumors. Finally tumor cells invade into the blood stream where characteristic
patterns of blood-borne metastasis indicate the onset of stage IV of disease. Particular tumors
vary in the extent to which they follow these phases in sequence (Kroon, 2004).
2

1. 2. 2 Malignant Melanoma
Melanoma is the most serious form of skin cancer. According to the Cancer Research Institute,
although melanoma accounts for only about 5% of all skin cancers, it is responsible for more than
75% of skin cancer-related deaths. Furthermore, melanoma cases in this country have more than
doubled in the past 2 decades, with the rise expected to continue. The American Cancer Society
projects that in 2007, the number of new cases of melanoma is estimated at 59,940, and the
number of fatalities estimated at 8,110 (Jemal, 2007). Furthermore, melanoma is projected to
affect 1 in 50 Americans by the year 2010 (Howe, 2003).

There are many risk factors that can lead to the onset of melanoma, including, but not limited to,
exposure to chemicals or ultraviolet radiation (Austin, 1984; Holman, 1986), diet (Mackie, 1980),
and genetic predisposition (Houlston, 1999). Exposure to sunlight appears to be the most
significant factor involved in the observed increase though; many dermatologists believe there
may be a link between childhood sunburns and melanoma later in life (Weinstock, 1989).

1. 2. 3 Clinical Presentation of Melanoma
Malignant melanoma is a neoplastic disease characterized by uncontrolled proliferation of
melanocytes, or the pigment of the skin. There are various forms of cutaneous malignant
melanoma, but the progression of disease in each form follows a similar pattern of growth and
clinical deterioration (Roses, 1983). The most benign types of melanoma are very slow growing
and, apart from a visible skin lesion, are generally symptomless. In many cases, it may take
several years to become invasive. Generally, the first sign of invasion by melanoma is an
increase in cell proliferation, or an increase of horizontal dimension across the surface of the skin,
often displayed as an aberrant growth. Further progression occurs by cell proliferation in the
3

vertical plane of the skin, or subcutaneous growth. The final growth patterns observed in the
progression of melanoma include the formation of local and distant metastases which often
proceed rapidly following the vertical expansion of melanoma (Roses, 1983).

1. 2. 4 Metastasis of Melanoma
Melanoma, as all cancers, is characterized by abnormal division of cells, combined with
malignant behavior of these cells. Metastasis is the unequivocal hallmark of the phenotypically
malignant cell. Malignant melanoma cells tend to spread, either by direct growth into adjacent
tissue through invasion, or by implantation into distant sites by metastasis, whereby the cancer
cells break away from the primary tumor and move through the bloodstream or lymphatic system
to other locations, and grow. Distant metastases can develop very rapidly, involving most
internal organs. The progression of a tumor from benign and localized to invasive and metastatic
growth is the major cause of poor clinical outcome in cancer patients (Hofman-Wellenhof, 1996).

1. 2. 5 Spontaneous Regression of Melanoma
Melanoma is an unusual cancer in that it exhibits a relatively high level of spontaneous regression
of the primary growth (approximately 7-8%; Smith, 1965; McGovern, 1972). The only other
malignant tumor that has demonstrated any degree of significant regression is renal cell
carcinoma (de Riese, 1991). Unfortunately though, primary melanoma regression is not always
considered a good prognostic sign, as metastases are often observed shortly thereafter (Kroon,
2004).

Histological observation of tissues present at the site of melanoma regression include a
lymphocyte infiltration of the papillary dermis that can range from a sparse peri-vascular
4

population all the way to a thick band of lymphocytes on the surface of the dermis (McGovern,
1972). Observations indicate that these lymphocytes are capable of cytotoxicity to melanoma
cells. The lymphocyte infiltrate also disappears following regression, implying that the response
is specifically mounted against the melanoma cells (McGovern, 1972).

1. 2. 6 Conventional Treatment of Melanoma
If melanoma is recognized and treated early, it is much more manageable and results in better
prognosis. If it remains undetected, it will spread or metastasize to other parts of the body. The
prognosis and treatment options for the treatment of melanoma depend on the many factors
including the stage of disease, the location and size of the tumor, the presence of bleeding or
ulceration at the primary site, and the patient's general health. Conventional treatment of
melanoma falls into three broad categories. The first method employed is surgery to remove
the tumor, which is the primary treatment of all stages of melanoma and by far the most
effective means of treatment provided it is detected early. In the presence of secondary
deposits and/or uncontrollable primary growth that make surgery impractical, another option
for treatment is chemotherapy. Chemotherapy is when drugs are used to stop the growth of
cancer cells, either by killing the cells or by stopping them from dividing. The third treatment
option for melanoma is radiation therapy, which uses high-energy x-rays or other types of
radiation to kill cancer cells or prevent them from growing (Kroon, 2004).

These conventional treatments are often plagued by a number of side effects and problems.
Most chemotherapy drugs are made to kill fast-growing cells, but because these drugs travel
throughout the entire body, they can also affect normal, healthy cells. Although radiation is
often localized, it can also damage normal cells and tissues. Damage to these healthy cells and
5

tissues is the cause of many side effects including, but not limited to, nausea and vomiting,
fatigue, soreness, rash, mental depression and anxiety, and hair loss. Additionally, these
treatments cause a decrease of a patient’s immune system, which can often lead to secondary
ailments. Similarly, surgery is often invasive and can lead to subsequent infection or other
problems.

Emerging novel therapies, such as the adoptive transfer of activated or engineered
lymphocytes for the treatment of certain cancers, are designed to overcome this vast array of
side effects. These new treatments use the body’s own immune cells to specifically target or
“home” to the site of the tumor. Furthermore, these immune effector cells are removed from a
patient prior to being manipulated and pretreated, followed by reintroduction back into the
patient. This potentially eliminates or lessens the risk of side effects due to harsh treatments in
vivo.

1. 3 Cellular Immunity and Cancer
1. 3. 1 Background
It has been over one hundred years since William Coley observed that tumor regression could
be induced by stimulating the immune system with bacterial toxins (Coley, 1893). He
reported that direct inoculation of bacteria into the site of a tumor, often led to high fever and
other symptoms associated with an intense immune response, but ultimately led to complete
regression in a fraction of patients with various types of advanced cancer. Coley’s work was
later reviewed by his daughter, where she detailed 30 complete remissions, which were
representative of the 270 complete remissions out of 1200 patients treated with toxins by her
father (Coley-Nauts, 1953). However, by the late 1930’s, this form of treatment was largely
6

abandoned in favor of radiotherapy and chemotherapy, which together with surgery are still
the major forms of cancer treatment today. In the mid 1970’s, it was theorized that tumor
necrosis factor and interferon(s) may have been the primary factors in the exhibited immune
response, however Coley’s results could not be reproduced to further study the exact
mechanism.

In spite of the mixed acceptance of this work, the concept of a role for the immune response in
the control and elimination of malignant cells survived, giving rise to a new theory. In 1959, it
was proposed that a specific, adaptive immune response may evolve so as to protect the body
from neoplasia. This theory was later termed the “immune surveillance” theory (Burnett,
1970), which stated that when aberrant cells with proliferative potential arise in the body they
will carry new antigenic determinant on their cell surfaces, which will trigger an immune
response to destroy the aberrant cells similarly to when an allograft (foreign tissue implant) is
destroyed. According to this theory, cancer would only develop due to some failure of
immune function, such as immunosuppression, or by adoption of immune evasion mechanisms
by the tumor. The extent to which this actually occurs in vivo remains a topic for debate, but
there is now considerable evidence to support this theory including spontaneous remission,
tumor infiltrating lymphocytes, and increased disease in immunosuppressed individuals
(Blattman, 2004). Therefore, many strategies for cancer treatment focus on augmenting the
immune system so as to increase its surveillance for, and subsequent destruction of cancer
cells.

More recently, some of the mechanisms that operate in the recognition and elimination of
tumor cells has been worked out (reviewed in Greenberg, 1991), and have suggested a key role
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for T lymphocytes in conferring the specificity of tumor rejections. There is also evidence for
natural killer cells (NK), macrophages, and eosinophil involvement in immune mediated antitumor activity (Silverstein, 1999).

In humans, direct evidence for a role of the immune response in immunity to tumors was
lacking for many years. The occurrence of spontaneous regressions of a number of tumors
(especially malignant melanoma), the presence of mononuclear cellular infiltrates in many
tumor types, and the response of certain tumors to immunotherapy all provided circumstantial
evidence of the presence of an immune response to the tumor in a proportion of patients, and
that immune intervention might provide a therapeutic strategy for human cancer.

1. 3. 2 Lymphocyte Recirculation and Infiltration
Lymphocytes are known to continuously circulate from blood to the lymphatic system via
lymphoid and nonlymphoid tissues to fulfill the function of immune surveillance (Masuyama,
1992). In 1964, James Gowans demonstrated that lymphocytes spend between 2 and 12 hours
in the blood before they appeared in the lymph or lymphoid organs (Gowans, 1964).
However, in order for lymphocytes to recirculate through tissues, they must initially adhere to
vascular endothelium and exit through the vessel walls in order to migrate through
neighboring cells and extracellular matrix to a damaged tissue. The vascular endothelium is a
single-cell layer that forms a continuous lining for the large container that holds circulating
blood. The majority of this lining is found in the microcirculation of the capillary beds, where
the surface area is very high, and the contact between the EC and blood components is
maximized (Silverstein, 1999). Leukocyte emigration from the blood through the endothelial
barrier during the inflammatory reaction is currently viewed as an adhesion cascade that
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involves a coordinated function of a variety of adhesion receptors on the surface of leukocytes
and EC (Carlos, 1994; Springer, 1994).

Acute inflammatory response mobilizes leukocytes to sites of inflammation, and results in
increased adherence of lymphocytes and other inflammatory cells to endothelium (Silverstein,
1999). Thus, the migration of lymphocytes across the vascular endothelial cell wall is a
prerequisite in the implementation of lymphocyte function (Oppenheimer-Marks, 1990). The
majority of lymphocytes are capable of tissue selective trafficking (termed “homing”),
recognizing organ-specific adhesion molecules on specialized EC (Butcher, 1980). A multistep model for leukocyte homing has been proposed and confirmed by various in vitro and in
vivo models. The first interactive step is the slow rolling of leukocytes along the endothelial
lining, which subsequently may result in firm adhesion, diapedesis, and finally transmigration
through endothelium into to surrounding tissue (Luscinska, 1996; Bevilacqua 1993; Springer,
1994; Butcher, 1991).

Clinical and pathologic evidence indicates that tumors can stimulate immune responses, such
as the presence of these mononuclear cell infiltrates (Kroon, 2004). These immune cells
respond to "danger" signals, which can be provided by growing tumors as a consequence of
the genotoxic stress of cell transformation and disruption of the surrounding
microenvironment. Under ideal conditions, these signals will induce inflammation, activate
innate effector cells with anti-tumor activity, and stimulate professional antigen-presenting
cells to subsequently trigger an adaptive response by T and B lymphocytes (Blattman, 2004).
The most potent of these cells is considered to be the natural killer, or NK cell (Hanna, 1980),
although other cells such as T-cells (Clark, 1988), monocytes (Tagliabue, 1979) and
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polymorphonuclear neutrophils (Kindzelskii, 1999), show considerable anti-tumor cell activity
after appropriate stimulation with cytokines or tumor cell products.

Further evidence for infiltration is provided by the observation of lymphocyte proliferation
(hyperplasia) in lymph nodes draining sites of tumor growth (Vetto, 1997). In many tumors,
there is evidence of cytokine effects, such as increased expression of class II major
histocompatibility complex (MHC) molecules (Sikorska, 1999), and intercellular adhesion
molecule-1 (ICAM-1; CD54) (Terol, 1998), suggesting an active immune response at the
tumor site. The spontaneous regression of tumors such as melanoma (Halliday, 1995), and
renal cell carcinoma (Jantzer, 1998), which are associated with dense peri- and intra-tumor
lymphocytic infiltrates, is also suggestive of an immune mediated anti-tumor response.

1. 3. 3 Leukocyte and Endothelium Interactions
Inflammation is marked by the migration of leukocytes and plasma to a site. This is
accomplished through an increased vascular permeability caused by retraction of EC and by
enhanced migration of leukocytes across the local vascular endothelium and in the direction of
the site of inflammation (Ugarova, 1998). Recirculating lymphocytes, monocytes, and
granulocytes bear receptors that bind to cell-adhesion molecules on the vascular endothelium,
enabling these cells to extravasate into the tissue (Shimizu, 1991; Diamond, 1990; Steeber,
1999).

Some of these adhesion molecules are expressed constitutively, while others are only
expressed in response to localized concentrations of cytokines produced during inflammatory
events. This process involves three main groups of adhesive mechanism; selectins (Abbassi,
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1993; Barkalow, 2000; Carlos, 1994), integrins (Carlos, 1994; Adams, 1997; Beekhuizen,
1993), and immunoglobulins (Carreno, 1995). Selectins are thought to be involved in the
initial rolling of leukocytes along the endothelium, after which integrin binding occurs,
followed by diapedesis into the underlying tissue. The β1 and β2 integrins are also important
mediators of leukocyte (and dendritic cell) adherence to CD54 (ICAM-1) and VCAM on EC
(Steeber, 1999).

1. 3. 4 Leukocyte and Endothelial Cell Adhesion
The mechanisms by which vascular EC capture circulating leukocytes are now well
characterized and many of the ligands that contribute to their adhesion and subsequent
transvascular migration identified (Osborn, 1992; Springer, 1994). Lymphocyte
transendothelial migration has been reported to be dependent on lymphocyte activation via
signaling through the T cell and the interleukin-2 (IL-2) receptor (Pryce, 1997). Furthermore,
to facilitate the retention and migration of leukocytes to an inflammatory site, both cell types
(leukocytes and EC) express outer surface cellular adhesion molecules (CAM's). When these
molecules are "activated", they undergo conformational changes increasing their affinity for
binding to complementary ligands.

Previous studies have also shown that initial capture of immune cells from the circulation
occurs via endothelial selectin molecules that result in weak attachment and, under conditions
of flow, result in leukocyte rolling along the vessel wall (Springer, 1994). Leukocytes further
bind to the adhesion receptors ICAM-1 and VCAM-1 on the endothelial surface before
undergoing transendothelial migration (Luscinskas, 1995; Shimizu, 1991). ICAM-1 is also
known to be involved in migration, independently of its role in adhesion, but the molecular
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basis of this function is poorly understood (Millan, 2006).
To further facilitate the retention and migration of leukocytes to an inflammatory site, there
are also a number of adhesion molecules present on the leukocytes that can mediate cell
adhesion. Four members of the ß2 subfamily of integrins have been identified: αMß2 (Mac-1,
CD11b/CD18, and CR3), α Lβ2 (leukocyte function–associated antigen and CD11a/ CD18),
αXß2 (p150,95 and CD11c/CD18), and αDβ2 (CD11d/CD18) (Van der Vieren, 1995; Larson,
1990). Two of the leukocyte β2 integrins, CD11a and CD11b, have been reported to bind to
ICAM-1 (and ICAM-2) on the tumor cell (Diamond, 1990, Male, 1994; Steeben, 1999). It has
previously been shown that CD11a, a member of the integrin family, is present on
lymphocytes and largely mediates adhesion between lymphocytes and EC. (Masuyama, 1992).
Furthermore, a tight binding event and subsequent migration through the EC wall has further
been shown to be mediated predominantly by the CD11a/ICAM-1 pairing (Oppenheimer,
1990; Oppenheimer, 1991; Kavanaugh, 1991; Yednock, 1992).
Many new strategies for the treatment of cancer focus on augmenting the immune system so as
to increase its surveillance for, and subsequent destruction of cancer cells. Furthermore, the
therapies are often based on augmentation or activation of such receptor/ligand pairs that are
present in leukocyte infiltration and subsequent attack of tumor cells.

1. 3. 5 Immunotherapy of Cancer
Immunotherapy refers to any approach aimed at mobilizing or manipulating a patient's
immune system to treat or cure disease (Steinman, 2004). It attempts to harness the power and
specificity of the immune system for treatment of malignancy as previously described.
Experiments in both mice and humans have established that the immune system can damage
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and in some cases destroy even very large established tumors (Muranski, 2006).
The various forms of immunotherapy may be classified into two main groups: active and
passive. Non-specific, active therapy involves activation of the immune system with agents
such as PHA (adjuvant therapy). Specific, active therapy includes vaccinating cancer patients
with tumor derived extracts. Unfortunately, clinical trials of tumor-specific active therapy (i.e.
vaccination) have so far been disappointing, with objective response rates of 5% or less
regardless of histology (Rosenberg, 2004).

Specific passive immunotherapy involves treatment with monoclonal antibodies directed
against tumor antigens. Treatment with tumor antigens, or tumor infiltrating lymphocytes
cultured with tumor antigens, are other forms of specific immunotherapy. Passive
immunotherapy may be non-specific, specific, or a combination of both. Non-specific
immunotherapy includes treatment with cytokines or LAK cells, which are discussed further
below.

1. 3. 5. 1 Interleukin-2 Activation of Lymphocytes
A clear example of the effectiveness of immunotherapy to mediate cancer regression comes
from studies of the administration of interleukin (IL)-2 to patients with metastatic melanoma
and metastatic renal cancer (Rosenberg, 1998).

Human IL-2 is a 15-kDa glycosylated interleukin, or hormone, that is only produced by
activated T-cells and functions primarily in the generation of cell proliferation and induction
of cytotoxic activity in activated T-cells, macrophages, and NK cells that is instrumental in the
body’s natural immune response (Robb, 1981). IL-2 has no direct effect on cancer cells,
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instead IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by
lymphocytes, the cells that are responsible for immunity (Smith, 1980).

There has been a total of 15% to 20% of patients with metastatic melanoma and metastatic
kidney cancer experience objective regressions of metastatic disease, almost half of which are
complete responses. With 20-year follow-up in some patients, it was shown that treatment with
IL-2 probably "cures" patients who experience a complete response, because 80% of these
patients have ongoing complete responses (Rosenberg, 2005). Further, only 6 of 33 patients
with either metastatic melanoma or kidney cancer who had complete cancer regressions have
ever had disease recurrence (Rosenberg, 1998). The treatment can be safely administered with
a treatment-related mortality of <0.5% (Kammula, 1998). Thus, it seems that patients with
metastatic melanoma and metastatic renal cancer join that very small group of patients with
solid tumors that can be cured by systemic treatment. Similar results from many series led the
Food and Drug Administration to approve the use of high-dose IL-2 for patients with
metastatic kidney cancer in 1992 and for patients with metastatic melanoma in 1998. The
durability of complete responses was a decisive factor in the approval of these treatment
regimens, which should be offered to all eligible patients with these metastatic cancers
(Rosenberg, 2005).

After the first descriptions of the effectiveness of IL-2 (Rosenberg, 1985; Lotze, 1986),
immunotherapy has come of age, and substantial improvements based on increased scientific
understanding have continued to develop.
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1. 3. 5. 2 Adoptive Immunotherapy
In clinical trials associated with the administration of IL-2, one major side effect was toxicity
using sufficient IL-2 concentrations to optimally activate the tumoricidal effect, presumably as
a result of leukocyte activation. To overcome this effect, the peripheral blood lymphocyte
population can be isolated from the patients using leukopheresis (or removal of leukocytes of
blood followed by subsequent replacement of depleted plasma and red cells to donor). These
cells are then activated in vitro with high doses of IL-2 to induce lymphokine activated killer
cells (LAK), which exhibit non-antigen dependent, non-MHC restricted cytotoxicity. LAK
cells were first described by Yron in 1980, and were originally thought to be a new class of
lymphocyte derived cytotoxic cell (Grim, 1982; Guinan, 1989). Since LAK behavior can be
derived from a variety of lymphoid cells, the term LAK is a description of a cellular activity,
rather than a specific cell type (Maghazachi, 1988). Following cellular activation, the cells
were washed and reintroduced into the patient’s circulation, where they were expected to
home to the tumors and kill them. This process is known as adoptive immunotherapy.
This adoptive transfer of autologous lymphocytes with antitumor activity, expanded in vitro
and reinfused into patients, can mediate tumor regression (Rosenberg, 1988), and recent
advances in this field have dramatically improved the effectiveness of this approach (Dudley,
2002, Dudley, 2003). In 2002, Rosenberg et al. reported some of their most promising results
to date. The procedure involved removal of peripheral blood lymphocytes from melanoma
patients, followed by reintroduction of LAK cells into the same patients. The results of their
studies were that the infused cells usually took up longterm residence, and in 10 of the13
patients, their melanoma cells, including all metastases, regressed either partially or
completely (Rosenberg, 2005). Lymphodepletion before the administration of autologous
tumor reactive cells has led to objective responses in 18 (51%) of 35 patients with metastatic
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melanoma, including those refractory to high-dose IL-2 and combination chemotherapy
(Dudley, 2005). These studies demonstrate the effectiveness of immune T cells when
administered to hosts actively depleted of T-regulatory cells, as well as cells that compete for
homeostatic cytokines.

Unfortunately, multiple factors, including tumor immune evasion, homeostasis and induction
of tolerance, as well as suboptimal quality of transferred T cells, have hampered the otherwise
promising attempts at driving tumor rejection (Ross, 1993; Yee, 2000; Dudley, 2001).

To overcome some of the homing and other problems associated with LAK based
immunotherapy, researchers have found immune cells deep inside some tumors, which have
an enhanced “homing ability”, and have named these cells tumor-infiltrating lymphocytes
(TILs). Success with TILs in lab animals led researchers to devise a strategy to increase the
anti-tumor activity of TILs. In the late 1980’s, clinical trials were begun by Rosenberg and
other groups (Rosenberg, 1985; Kawakami, 1988; Heo, 1987), in which tumor infiltrating
lymphocytes (TIL) were removed from excised tumors, stimulated with IL-2, and reinjected
into cancer patients to promote tumor regression.

Furthermore in a 2006 report, the Rosenberg group reported a 50% response rate according to
RECIST criteria was reported in patients with metastatic melanoma treated with in vitro
expanded TIL’s and IL-2 following a lymphodepleting nonmyeloablative preparative regimen
of cyclophosphamide and fludarabine (Gattinoni, 2006; Hughes, 2005; Morgan, 2006). Using
this method, 2 out of 6 patients had a regression period of over 2 years following treatment
(Gattinoni, 2006). This significant achievement was attributed to the key realization that the
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host’s immune system needs to be properly conditioned, in order to create an appropriate
‘lymphoid space’ that is devoid of regulatory mechanisms. However, immunodepletion and
adoptive therapy have not yet been tested in randomized studies, but the results of recent
clinical trials using these methods are notable for their unprecedented response rates and the
fact that the patients studied had previously failed other modes of immunotherapy including
high-dose IL-2 and ACT (Dudley, 2002; Morgan, 2006).

Although encouraging, the sporadic results obtained with adoptive immunotherapies may be
explained if activated leukocytes interact in a more complex way with other molecules and cells
in the circulation. These interactions have not been extensively studied, but there is mounting
evidence that molecules of the blood coagulation system may play a major role in the modulation
of the immune response. The following section brings together the interactions of the end
products of the clotting system (fibrinogen and fibrin) with immune cells and EC with relevance
to inflammation and cancer.

1. 4 The Role of Fibrin(ogen) in Immunity and Cancer
1. 4. 1 Background
A relationship between cancer and abnormalities of the coagulation system has been recognized
for over 100 years (Trousseau, 1865). Thromboembolic disease (usually of unknown etiology),
refractory to anticoagulant therapy, may be an early detectable sign of an underlying cancer,
which could precede the onset of observable cancer by months or years. Although many cancer
patients exhibit clinically significant hemostatic abnormalities, about 50% of all patients (> 90%
with metastases) also have abnormal laboratory coagulation parameters (Trousseau, 1865). Such
parameters include soluble fibrin (sFn) (Gouin-Thibault, 1999; Iversen, 1995; Nakagawa, 1994),
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and its precursor fibrinogen (Fg), which may also be an early marker of undiagnosed malignancy
(Andrassy, 1980).

A role for coagulation in tumor biology is further inferred by the anti-tumor effects of
anticoagulant drugs, such as heparin or warfarin (Zacharski, 2005; Biggerstaff, 1997) and in a
number of both experimental and spontaneous animal tumor models (Hilgard, 1976; McCulloch,
1987; Eichbaum, 1975; Biggerstaff, 1997). However, these therapies also increase the risk of
bleeding due to inhibition of normal clotting.

1. 4. 2 Fibrin(ogen) and Soluble Fibrin in Disease
During the past two decades there has been an increasing appreciation of the multifaceted role
fibrin(ogen) plays in the immune and inflammatory reactions. Although presumed for many
years, many of the roles attributed to fibrin(ogen) have only recently been substantiated. In this
regard, much of the available evidence indicates that fibrin(ogen) operates as an antagonist, or
that the adhesive potential is realized in a host of diseases and contributes to the progression of
those diseases. We, and others, have speculated that tumor growth and propagation by
fibrin(ogen) may be an inadvertent consequence of the protein's role in inflammation.
Furthermore, some researchers are willing to attribute some or most of the pathogenesis of cancer
to adhesive inflammatory events involving fibrin(ogen) (Palumbo, 2002; Simpson-Haidaris,
2001; Retzinger, 1999). Presuming their ideas are correct, interfering with those events should
mitigate disease.

Following its secretion from the liver, the protein exists in plasma, the lymph, and interstitial fluid
(Chrobak, 1967; Le, 1998). Fibrinogen is a classic "acute-phase reactant," with serious
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inflammatory challenges resulting in increased hepatic expression, the induction of extrahepatic
expression, and increased circulating protein (Molmenti, 1993; Lee, 1996; Guadiz, 1997). In
healthy individuals, the concentration of fibrinogen in plasma is reported to be between 4 and 10
µM (Retzinger, 1999). However, this concentration can increase by as much as 200 to 400%
during times of physiological stress, such as disease (Shultz, 1990).

Fibrin(ogen) deposition is a universal feature within injured tissues and inflammatory foci. In the
late 1950's, fibrin(ogen) was shown to be a component of tumor-induced inflammation, and more
recently fibrin(ogen) (and derived materials like fibrin) have been shown to accumulate within
tumor stroma and envelop tumor cells (Retzinger, 1999). Furthermore, in vitro studies (Smiley,
2001; Sitrin, 1998; Rubel, 2002; Rubel, 2001; Shi, 2001) have shown that fibrin(ogen) can
profoundly alter leukocyte function, leading to changes in cell migration, phagocytosis, NF-kappa
B–mediated transcription, production of chemokines and cytokines, degranulation, and other
processes. Furthermore, recent reports from in vivo studies suggest that pulmonary metastasis is
reduced in fibrinogen deficient animals (Palumbo, 2002).

The presence of sFn in blood has, until recently, been considered a benign marker for the
presence of an ongoing coagulopathy. However, others have reported a direct role for sFn in
melanoma metastasis in an experimental animal model (Rickles, 1992; Biggerstaff, 1999).
Several other studies suggest that sFn may be a prognostic marker in cancer (Beer, 2002; Spero,
1980), but no clinical studies have been performed to date to directly associate sFn with increased
metastasis.

Furthermore, in solid tumors and in experimental systems, the presence of polymerized fibrin has
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been reported to result in inhibition of the immune response to cancer. Gunji et al. showed that
fibrin deposition on tumor cells during migration in the blood could protect them from
elimination by NK cells or other cytotoxic cells (Gunji, 1988). Furthermore, this was also found
particularly when using immunotherapies involving lymphokine (Interleukin-2) activated killer
(LAK) cells (Gunji, 1999), mitogen (PHA) stimulated T cell blasts, or re-injected
tumorinfiltrating leukocytes (TIL). Furthermore, immunosuppression induced by fibrin
degradation products has also been reported (Girmann, 1976; Donnel 1989). Furthermore, our
laboratory also recently demonstrated that sFn also inhibited lymphocyte and IL-2 activated LAK
cell adherence and cytotoxicity against tumor cells (Figures A-1, A-2; Biggerstaff, 2007). All of
these results collectively suggest that sFn may be an immunosuppressive agent in cancer, and that
it is involved in the etiology of metastasis. Furthermore, successful transfer and treatment by
these means are more commonly observed in those patients with less severe, early stage disease.
This coincides with the findings that sFn is more elevated in those patients with severe prognosis.
These pieces of information taken collectively, support the hypothesis that sFn is an
immunosuppressive agent that inhibits lymphocyte recognition, binding, and diapedesis of
endothelium, which allows for greater success of metastasis.

1. 4. 3 Fibrinogen Structure and Degradation
Fibrinogen is a dimeric protein, each half of which is composed of disulfide-bonded polypeptide
chains designated Aα, Bβ, and γ. The designations "A" and "B" refer to fibrinopeptides A (FpA)
and B (FpB) that constitute the amino terminal residues of the A and B chains (Retzinger, 1999).

The conversion of fibrinogen to fibrin manifests as a multi-step transformation of the original
conformation into both water-soluble monomers and gel-like polymers. The initial steps of this
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are catalyzed by thrombin, a trypsin-like serine protease, which hydrolyzes specific Arg-Gly
bonds within the α and β chains of fibrinogen (Retzinger, 1999). Figure 1.1 is a diagram of
fibrinogen structure and its sites of thrombin cleavage.

Fibrinogen is thought to be rather inert in circulation but it becomes reactive toward itself and a
number of proteins and cell types upon conversion to fibrin (Medved, 2001). Conversion of
fibrinogen to fibrin results in the exposure of multiple binding sites that provide its interaction
with various other proteins and cells (Medved, 2001). Furthermore, fibrin(ogen) has been shown
to suppress lymphocyte functions (Plow, 1986).
As earlier discussed, there are an abundance of cells present near those sites of inflammation, or
cancer growth that have receptors for fibrin(ogen). Fibrin(ogen) binds to a wide range of cellular
receptors, including two of the leukocyte β2 integrins, αMβ2 (Mac-1) and αXβ2 (p150,95)
(Wright, 1998; Altieri, 1995; Altieri, 1988), and the β2 integrin receptor, CD54 (ICAM-1)
(Languino, 1995; Gardiner, 1997), which are important mediators of leukocyte diapedesis. Many
of the effects of fibrin(ogen) on leukocyte activity appear to be mediated by a specific receptor on
leukocytes, the integrin receptor CD11b (αMß2) (Flick, 2004; Takami, 2002; Tang, 1993).

Figure 1-1. Fibrinogen structure (Tollefsen, online).
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1. 4. 4 Anticoagulation Therapy of Cancer
Fibrin deposition around solid tumors may protect the host from tumor cell invasion by blocking
their entrance into the circulation (Colucci, 1981). Furthermore, early studies using isotope
labeled tumor cells showed that tumor cell deposition occurred regardless of whether animals
were anticoagulated, but that subsequent metastatic growth was decreased by anticoagulant
therapy, implying a role for fibrin in metastatic tumor growth (Fisher, 1967). Recently,
Costantini and Zacharski reviewed the evidence addressing the significance of blood coagulation
activation in fibrin deposition in tumor cells (Costantini, 1993). As for the involvement of
fibrin(ogen) in malignancy, it has been proposed that the protein envelops tumor cells thereby
protecting them from immune surveillance (Dvorak, 1981), and provides an intravascular matrix
for trapping and anchoring malignant cells following their release from a parent tumor.(Markus,
1984). A role for coagulation in tumor biology is further inferred by the anti-tumor effects of
anticoagulant drugs, such as warfarin and heparin (Zacharski, 2005), and other coumadin
derivatives (Gasic, 1983), thrombin inhibitors (Hu, 2004; Asanuma, 2004), and in a number of
both experimental and spontaneous animal tumor models (Hilgard, 1976; McCulloch, 1987;
Eichbaum, 1975; Amirkhosravi, 1995).

Anticoagulant therapy, in combination with chemotherapy, has been applied with some success in
the past. However, anticoagulation can be seen as a drawback in many patients, particularly those
undergoing surgery, because excessive blood loss can result. Recently, alternative approaches
have been applied in the treatment of cancer, that do not interfere with the natural coagulation
patients.
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1. 5 Peptide Therapy
1. 5. 1 Background
There are multiple examples in nature, where peptides are used as ligands to influence the
function of specifically binding target proteins (Buerger, 2003). Furthermore, there is a wide
spectrum of tools now used to interfere with the function of a given gene product, including
selected inhibitory peptides (Borghouts, 2005). Most peptides being considered for therapeutic
purposes at this time exert their action on the cell surface. Peptides bind to cell surface proteins
and act by inducing or inhibiting one or more signal transduction pathways. Furthermore, small
peptides are able to recognize specific protein domains and thus interfere with enzymatic
functions or protein-protein interactions (Buerger, 2003). Proteins and peptides are
experimentally selected for high-affinity cellular interactions with pre-determined target
structures that are emerging as important molecules. These advances could serve to extend the
conventional administration of drugs. In a few model systems, peptides have already been used
to manipulate crucial regulatory networks in cancer cells (Buerger, 2003; Kardinal, 2001; Mai,
2001; Wang, 2000; Zhang, 2001). They can target specific intracellular proteins required by
cancer cells for proliferation and invasion. It is conceivable that individual peptides can also be
derived to inhibit function in a targeted fashion. These peptides can be used for mono therapy or
in combination with conventional chemotherapeutic agents in order to better treat cancer
(Borghouts, 2005).

1. 5. 2 Natural vs. Synthetic Peptides
Inhibitory peptides can either be designed from both naturally occurring binders or synthetically
manufactured. Usually crystallographic data are required for the first approach, to study the
interaction surface between the target protein and the binding partner (Borghouts, 2005). Several
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findings (reviewed in Borghouts, 2005) indicate that peptides with high affinity already exist for
various targets, which can be used for therapeutic approaches without screening large peptide
libraries.

Furthermore, the use of small endogenous domains not only provides for high affinity, but also
circumvents problems encountered with larger exogenous proteins, such as lower stability and
higher immunogenicity if used in vivo (Borghouts, 2005). Unfortunately, the clinical fruits of
many new therapeutic methods have not been abundant, in part because in vitro models used for
screening often do not duplicate well in vivo. This too has been true of the past decade of
peptide-drug design for the treatment of cancer. There are clear indications that smaller ligands
are generally better for therapeutic use (Reilly, 1995). Compared with antibodies and their
fragments, peptides are considerably smaller, and generally should not elicit an immune response
upon repeated administration (Aina, 2002; Nilsson, 2000). Therefore, peptide ligands may
overcome several limitations of antibody therapy and diagnosis (Mori, 2004).

Furthermore, what is needed is the therapeutic equivalent of what Muller et al. refer to as “smart
bombs”, or the ability to selectively inhibit inflammation where it is damaging without interfering
with beneficial functions of the inflammatory response (Muller, 2002). Many current strategies
lack this ability, and cause an added difficulty when dealing with any disease, particularly those
associated with surgery.

1. 5. 3 Specific Peptide Therapeutics
As previously discussed, fibrin(ogen) is a ligand for many biological molecules. It has been
reported to bind numerous integrins, including those present on many leukocytes (monocytes,
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neutrophils, and lymphocytes), EC, and tumor cells. Many different studies have been performed
to further identify the specific amino acid sequences on these molecules responsible for
interactions. Furthermore, small peptides have been derived from fibrinogen, CD11b/CD18, and
CD54, and tested for their ability to inhibit fibrinogen binding (Altieri, 1995; Ugarova, 1998;
Yakubenko, 2001; D’Souza, 1996). Several other similarly derived peptides have been identified
during the past several years, but these four specific sequences (and peptides) have been studied
in detail by our lab (Biggerstaff, 2006). In recent studies, it was shown that the following four
peptides sequences significantly restored monocyte adherence (and cytotoxicity) to tumor cells,
following pretreatment with (and inhibition caused by) sFn (Biggerstaff, 2006). Furthermore,
Table 1-1 details the sequences, molecules of origin, and ligands associated with each peptide.

1. 5. 3. 1 Peptide P1 Background
Peptide 1, (P1; 117NQKIVNLKEKVAQLEA133 ) present on the fibrinogen γ-chain, reportedly
binds to the CD54 sequence present on the 1st immunoglobulin domain (Altieri, 1995). As
previously discussed, ICAM-1 is expressed by many cell types including EC, leukocytes and
many cancers. Furthermore, pretreatment of tumor cells with P1 was shown to block sFn from
binding to tumor cells in our recent work (Figure A-3; Biggerstaff, 2006).

Table 1-1. Specific Peptide Sequences, Molecules of Origin, and Ligands (Biggerstaff, 2006).
Peptide #

Sequence

Molecule of Origin

Ligand

P1

NNQKIVNLKEKVAQLEA

sFn (g-chain)

CD54 (1st Ig)

P2

YKSMKKTTMKIIPFNRLTIF

sFn (g-chain)

αMβ2 (αM I)

P3

KVILPRGGSVLVTC

CD54 (1stIg)

sFn (g-chain)

P4

KFGDPLGYEDVIPEADREG

αMβ2 (αM I)

sFn (g-chain)
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1. 5. 3. 2 Peptide P2 Background
Several peptides corresponding to potential fibrin(ogen)/CD11b binding domains have been
identified over the past several years. Recently, Ugarova et al. revealed another possible binding
site in the region of 377–395 of the fibrinogen chain that may be important (Ugarova, 1998).
Furthermore, the P2 peptide (377YKMKKTTMKIIPFNRLTIG395), originally designated P2C, was
shown to significantly inhibit CD11b-mediated cell adhesion to immobilized fibrinogen and
directly supported saturable binding to the M I-domain (Ugarova, 1998). It is currently considered
to be the major fibrin(ogen) γ-chain binding site for CD11b (αMβ2) and CD11c (αXβ2) (Ugarova,
1998). Furthermore, pretreatment of monocytes with P2 has recently been shown to block sFn
from subsequently binding to cells, allowing restoration of binding to tumor cells (Figure A-3;
Biggerstaff, 2006).

1. 5. 3. 3 Peptide P3 Background
The major fibrin(ogen) binding site on CD54 is in the 1st Immunoglobulin domain
(8KVILPRGGSVLVTC21, designated P3 herein) (D’Souza, 1996), and binds to the fibrinogen γchain. Pretreatment of sFn with P3, prior to exposure to monocytes, has also been recently shown
to restore monocyte binding to tumor cells (Figure A-4; Biggerstaff, 2006). Specifically, P3
binds the site taken to synthesize P1 herein (117NQKIVNLKEKVAQLEA133 ).

1. 5. 3. 4 Peptide P4 Background
The major fibrin(ogen) γ-chain binding site reported on CD11b (αMβ2) is in the αM I-domain
(245KFGDPLGYEDVIPEADR261) (Yakubenko, 2001). Peptide 4 (P4) was created from this
sequence, in order to block leukocyte binding to fibrin(ogen). Furthermore, pretreatment of sFn
with P4 prior to exposure to monocytes, was recently shown to partially restore immune cell
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binding to tumor cells (Figure A-4; Biggerstaff, 2006). Figure 1.2 is a schematic diagram
showing the sequences and specificities of each of these peptides on the sFn γ-chain and on
CD11b (αMβ2) and CD54.

As previously discussed, earlier studies (Biggerstaff, 2006), have shown that the addition of
any/all of these peptides results in a significant restoration of adherence of sFn pretreated
monocytes and tumor cells to one another (by a mechanism of CD11b and CD54; Figure A-5).
However, since this project employs only lymphocytes and EC, the peptides designated P1 and
P3 are being tested for their anticipated relevance to this model. Whereas, P2 and P4, which are
specific to the monocyte receptor and complementary sequence on sFn, were not expected to
exhibit the same therapeutic potential for these particular cell types (due to the different
expression of receptors).

Additionally, previously performed experiments determined that the specific fibrin(ogen)
adherence inhibitors did not affect fibrinogen clotting in the presence of thrombin in vitro.
Furthermore, the peptides did not inhibit the normal coagulation cascade, as shown in re-calcified
normal human plasma (Biggerstaff, 2006).

1. 6. Research Objectives and Hypotheses
There are seemingly many factors that are physiologically relevant to the epidemiology of disease
and prognosis in melanoma patients. Furthermore, the relationship between host immune cells
(leukocytes), the vascular system (endothelium), tumor cells, the cytokine network, and potential
therapies is highly complex, as discussed. Therefore, the primary goal of this project was to
further elucidate the details of these interactions. This will allow the identification of possible
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Figure 1-2. Model of Relevant Cellular and Fibrin(ogen) Receptor Sequences.
Schematic diagram showing the amino acid sequences, sites of origin and effector
molecules for four peptides (designated P1 – P4) reported to inhibit fibrin(ogen) binding
to CD11b/CD18 or Mac-1 (orange) and CD54 (blue) (Biggerstaff, 2006 adaptation).
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synergistic interactions and inhibitory factors involved in tumor cell progression and metastasis.

As presented above, fibrin(ogen) and sFn levels are often upregulated in cancer patients, and have
been shown to act as immunosuppressors in many experimental animal models. Furthermore, our
lab has recently shown that sFn inhibits monocyte adherence to and cytotoxicity of tumor cells.
More recently, we have found that sFn also inhibits lymphocyte and LAK cell adherence to tumor
cells.

There is also an abundance of evidence that these interactions are highly dependent on the
CD11b/CD18, CD11b/CD18, and CD54 receptor interactions. More specifically, sequences
within these receptors have been identified that actively mediate binding to fibrin(ogen).
Furthermore, researchers have discovered complementary sequences that have been recently
identified on the fibrin(ogen) molecule that bind specifically to these sequences. As a result, we
have utilized these specific peptide sequences that have been shown to significantly restore levels
of monocyte binding and cytotoxicity to tumor cells, even in the presence of sFn.

Based on these results, it was hypothesized that sFn may also inhibit lymphocyte and LAK cell
adherence to and diapedesis through EC. We further hypothesized that a double blockade of sFn
binding to CD54 on EC, using the above peptides (P1 and P3), would result in restoration of these
effector functions without affecting normal clotting. Further pretreatment with P2 and P4, those
peptides specific for monocyte interactions, are expected to minimally affect binding and
migration, due to the incongruence of receptor and ligand in this model.

In this project, four specific aims have been identified that test these hypotheses including, 1) to
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use immunochemistry and fluorescently labeled sFn to establish sFn binding to effector cells, 2)
to determine the role of sFn in lymphocyte adherence to EC under flow conditions, 3) to
determine the role of sFn in lymphocyte transmigration, or diapedesis through endothelium
toward tumor cells in a standard microplate assay, and 4) to determine the effect of specific
blocking peptides on sFn-induced inhibition of lymphocyte binding and diapedesis.

Inhibition of lymphocyte function by sFn would have important implications in adoptive
immunotherapy of cancer in which activated, or modified lymphocytes are reintroduced into the
circulation of cancer patients to kill metastatic cancer cells and to extravasate and home to solid
tumors.
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CHAPTER 2. EXPERIMENTAL DESIGN, MATERIALS, AND METHODS
2. 1 Experimental Design and Background
2. 1. 1 HMEC-1 Endothelial Cells
Human dermal microvascular endothelial cells (HMEC-1) were immortalized by transformation
with SV40 virus (Ades, 1992). This particular cell line was chosen for its previously documented
characteristic endothelial cell receptor biology, in order to further explore the complex
relationship between lymphocytes, tumor cells, and endothelium.

HMEC-1 exhibits typical cobblestone morphology when grown in monolayer culture (Figure
2.1). It has previously been shown to bind to peripheral blood leukocytes and extra cellular
matrix proteins via many specific cell adhesion molecules. HMEC-1 can either constitutively
express or can be induced to express key integrins including alpha-1,-2,-3,-4,-5,-6, and –V, as
well as beta-1,-3,-4 and -5. Furthermore, they have been shown to express immunoglobulin gene
super family molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1), and a member of the selectin family, E-selectin (Xu, 1994).

2. 1. 2 A375 Melanoma Cells
The A375 human amelanotic malignant melanoma cell line was established from a solid tumor
that was excised from a 54 year-old female with melanoma as described in Giard, et al. (Giard,
1973). This cell line was chosen due to its relevance to immunotherapy (melanoma) and due to
its employment in our previous publications involving similar mechanisms. Furthermore, A375
cells express CD54, which has been reported on many cancerous and endothelial cell lines
(Steeber, 1999).
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Figure 2-1. Confluent HMEC-1 endothelial cells (60x magnification).
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2. 1. 3. Immunostaining and Fluorescently Labeled Soluble Fibrin Assays
2. 1. 3. 1 von Willebrand’s Factor
Endothelial cell ultrastructure was initially described by Weibel et al. in the 1960’s. The cells
contain numerous unique, electron-dense, membrane-bound organelles, called Weibel-Palade
bodies (Weibel, 1964). These particular structures contain a high concentration of von
Willebrand factor (vWF), a large glycoprotein present in plasma. When EC are exposed to
certain agonists, such as thrombin or histamine, these Weibel-Palade organelles “flow” to the
surface of the cell and their contents are secreted into the blood, causing fusion between their
membranes and the cellular surface. Therefore, HMEC-1 cells were stimulated with thrombin
(which is necessary to convert Fg to sFn) and immunostained for vWF.

2. 1. 3. 2 CD54 (ICAM-1)
The CD54 antigen is a 90 kDa transmembrane glycoprotein, which is related to the
Immunoglobulin family. As previously discussed, the CD54 antigen has been reported to
mediate the adhesion of lymphocytes, monocytes, and neutrophils to both normal and activated
endothelium. Therefore, HMEC-1 cells were stimulated with thrombin and stained for this
antigen using indirect immunostaining to confirm presence of this receptor on this cell line.

2. 1. 3. 3 CD25
CD25, or Anti-IL-2R, recognizes an antigen that is the human low-affinity interleukin-2 receptor
(IL-2R). Furthermore, CD25 expression is reported to be upregulated on activated lymphocytes,
or LAK cells, compared to their lymphocyte precursors (Schlossman, 1995). Therefore,
monoclonal antibodies directed against this receptor were applied to differentiate these different
cell types after incubation for 72 hours.
33

2. 1. 3. 4 Oregon Green Labeled Soluble Fibrin on Effector Cells
In previous studies, we have shown that Oregon Green labeled soluble fibrin binds to monocytes,
lymphocytes, and A375 tumor cells (Figures A-6, A-7; Biggerstaff 2006, 2007). In this project,
we have employed the same method to show that sFn also binds to LAK and HMEC-1 cells.

2. 1. 4 Leukocyte Adherence to Endothelial Cells Under Flow Conditions
As earlier reported, postcapillary venules are major sites of leukocyte emigration in inflammation
(Lawrence, 1990). Furthermore, physiological shear rates in these regions are generally reported
to be between 35-560 s-1 (Lawrence, 1990; Heisig, 1968). In general, the movement of leukocytes
to the vessell wall and subsequent efficiency of attachment both depend on the blood flow,
therefore utilization of a perfusion model is more physiologically relevant than other static, cell
binding methods that are often employed (Abbitt, 2003). Furthermore, our work previously
included performing optimization assays for our particular flow model, in order to employ a shear
rate that falls within this reported range while still observing a significant number of binding
events (Figure A-8; Biggerstaff 2006).

To simulate the fluid shear stresses present in vivo, coverslips containing confluent endothelial
cell monolayers were loaded into the FCS2 stage incubator (Bioptechs Inc., Butler, PA), on the
stage of an inverted microscope to observe lymphocyte rolling and binding events. The FCS2
incubator is a closed, near-laminar flow, temperature-controlled perfusion chamber. Figure 2-2
shows the detailed setup of the apparatus.
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Figure 2-2. Bioptechs FCS2 System. A) Eight piece apparatus (1. Temperature
sensors, 2. Heater contacts, 3. Perfusion connections, 4. Upper gasket, 5.
microaqueduct slide (optical surface, perfusion guide and termperature control), 6.
Lower gasket (defines flow geometry), 7. 40mm coverslip, 8. Self-locking base
with internal temperature control), B) Microperfusion flow chamber, C) fully
assembled apparatus.
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2. 1. 5 Lymphocyte Transmigration Through Endothelial Cells in Microplate Assays
A static, transwell migration system (adapted from Sancho, 1999) was used to perform
experiments to determine the ability of lymphocyte and LAK cell preparations to cross
endothelium in the presence or absence of an underlying tumor layer. Furthermore, the role of
various levels of sFn in inhibiting lymphocyte/LAK cell diapedesis was also explored. Lastly,
specific peptides were also added to the model, in addition to sFn, in order to test their abilities to
restore the protein from inhibiting diapedesis.

2. 2 Sterile Cell Culture Methods
All cell culture was carried out under sterile conditions, and performed in a Class 2 biological
safety cabinet following the University of Tennessee BSL-2 laboratory guidelines.

2. 2. 1 Endothelial Cell Culture
HMEC-1 (kindly provided by Dr. Tim Sparer) were cultured in high-glucose DMEM (Invitrogen,
Carlsburg, CA) supplemented with 10% Fetal Bovine Serum (FBS; Atlanta Biologicals, Atlanta,
GA), 2 mM L-glutamine (Hyclone, Logan, UT), and 100 µg/ml streptomycin/penicillin
antibiotics (Hyclone). They were grown in both 25 cm2 and 75 cm2 sterile tissue culture flasks
(Costar, Cambridge, MA) at 5% CO2, at 37ºC in constant culture.

2. 2. 2 Tumor Cell Culture
A375 was purchased from ATCC (Rockville Pike, MD), and maintained in continuous cell
culture in RPMI 1640 supplemented with Glutamax (Invitrogen) with 10% FBS, and 100 µg/ml
streptomycin/penicillin antibiotics. They were grown in both 25cm2 and 75cm2 sterile tissue
culture flasks at 37ºC at 5% CO2.
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2. 2. 3 Removal of Cells from Culture
Cells were detached from the plastic flasks using approximately 3-6 ml (depending on flask size)
of trypsin/EDTA (0.25%; Hyclone). After trypsin was added, the flask was immediately placed
into a 37ºC incubator, with 5% CO2 for approximately 4-6 min, or until cells dislodged easily
from the plastic. The cell suspension was transferred from the flask into a 15 ml centrifuge tube
and topped off with RPMI 1640 with 10% FBS. Cells were then centrifuged at 200 x g for 10
min, to obtain cell pellets.

2. 3 Isolation of Peripheral Blood Lymphocytes
Venepuncture and disposal for this study was performed in accordance with the University of
Tennessee Institutional Review Board approval (IRB# 6788B).

2. 3. 1 Venepuncture
Approximately 50 milliliters of peripheral blood were drawn from normal, healthy volunteers into
6 ml 3.2% lithium heparin vacutainers (Becton Dickinson VACUTAINER™ Systems,
Rutherford, New Jersey).

2. 3. 2 Isolation of Lymphocytes
Whole blood was immediately transferred from 6 ml vacutainers into a 75cm2 sterile tissue
culture flask and diluted by approximately 50% with RPMI 1640. The cell suspension was
separated using a density gradient centrifugation method created by Boyum in 1976, which
isolates peripheral mononuclear cells from whole blood (Boyum, 1976). Approximately 8 ml of
Lymphoprep (Axis-Shield, Oslo, Norway) was added to 8 separate universal containers (Dynalab,
Rochester, NY). Subsequently, 13-15 ml of diluted blood was gently layered over media, using a
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sterile pipette. All tubes were then centrifuged at 450 x g for 25 min. A distinct layer of
mononuclear cells was extracted from each container, using a sterile, manual 2 ml pipet, and
condensed into 4 fresh universal containers. The cell suspension was then topped off to fill the
containers, and 3 additional centrifugation steps were performed to compound all cells present
from the separation into one pellet. Isolated cells were transferred into another tissue culture flask
containing 20 ml of RPMI 1640 with 10% FBS, and incubated at 37°C, in 5% CO2, for 90 min in
order to allow monocytes to adhere to the plastic, while the non-adherent cells (lymphocytes)
remain in suspension. The lymphocyte suspension was decanted into a new universal container,
topped off with RPMI 1640 and centrifuged at 200 x g for 10 min. A cell count was performed
on the final cell suspension in an improved Neubauer counting chamber by diluting whole blood
by adding 10 μl of blood into 90 μl of Trypan Blue stain (Sigma, St. Louis, MO). Cell purity was
also determined by differential counting of lymphocytes and monocytes using MayGrunwald/Giemsa stain (Sigma, St. Louis, MO). In all experiments, the mean lymphocyte purity
was determined to be 91 ± 5%.

2. 3. 3 Preparation of LAK Cells
Non-adherent lymphocytes derived from 50 ml of blood were further divided into two aliquots
containing equal number of cells when experiments were planned to include LAK cells. The cells
were centrifuged, the pellets resuspended, and counted to 1 x 106 cells/ml in either RPMI 1640
with 10% FBS (control cells) or RPMI 1640 with 10% FBS, supplemented with IL-2 (2.5 ng/ml
final concentration; R&D Systems, Minneapolis, MN) to make LAK cells. Lymphocytes (both
aliquots) were incubated at 37ºC upright in 25cm2 tissue culture flask for approximately 72 hours.
After this time, the cell suspensions were decanted into universal containers, washed by
centrifugation at 200 x g two times in RPMI 1640 to remove any residual IL-2, and a cell count
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and viability assessment performed prior to their inclusion in experiments.

2. 3 .4 Assessment of Cell Numbers and Viability
Leukocyte, tumor cell, and endothelial cell number and viability were determined by the addition
of 10 µl of cell suspension to 90 µL of Trypan Blue (Sigma; St. Louis, MO). The cell
suspensions were placed in an improved Neubauer hemocytometer chamber. The number of cells
occupying the central 20 squares was counted and divided by 10, so as to obtain the concentration
of cells required (in µl) to obtain a 106 cells/ml final concentration in one milliliter of media.

2. 4 Immunochemistry
2. 4. 1 Immunostain: von Willebrand’s Factor on HMEC-1
HMEC-1 cells were adjusted to 5 x 106 cells/ml in one milliliter of RPMI 1640, in sterile 5 ml
falcon tubes. The specific monoclonal antibody against von Willebrand’s Factor (Clone 4F9;
Beckman Coulter, Miami, FL), or isotypic control (IgG1 (mouse); Clone 679.1Mc7; Beckman
Coulter) was added to the cell suspension and incubated at room temperature for 30 min.
Equivalent concentrations/volumes of primary antibody and isotypic control were used (5 µg/µl).
Following initial incubation, tubes were centrifuged at 200 x g for 10 min to wash cells. The
supernatant was discarded and subsequently 10 µl (5 µg) of secondary antibody (Oregon Green
labeled, mouse-anti-goat; Beckman Coulter) was added to 1 milliliter of RPMI 1640, which was
added to the HMEC-1 pellet and incubated at room temperature for 30 min. The cells were again
washed via centrifugation at 200 x g for 10 min. The supernatant was discarded and the cells
were resuspended with 1 milliliter of 1% PFA in falcon tubes for 30 min, followed by an
additional centrifugation step. The cell pellet was resuspended in 500 µl of RPMI 1640 and 10 µl
of cell solution was transferred to standard microscope slides, mounted with Prolong Antifade
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Reagent (Invitrogen, Carlsbad, CA), and sealed with 13mm x13mm pieces of cover glass.

2. 4. 2 Immunostain: CD54 (ICAM-1) on HMEC-1
HMEC-1 cells were adjusted to 5 x 106 cells in one ml of RPMI 1640, in sterile 5 ml falcon tubes.
Ten µl of human-anti-mouse CD54 monoclonal antibody labeled with FITC conjugate (Clone
84H10; Beckman Coulter), or isotypic control (IgG1; Clone 679.1Mc7; Beckman Coulter) were
added, and incubated for 30 min at room temperature. Equivalent concentrations/volumes of
primary antibody and isotypic control were used (5 µg/µl). Following incubation, tubes were
centrifuged at 200 x g for 10 min. The supernatant was discarded and the cells resuspended and
fixed with 1 milliliter of 1% PFA in falcon tubes for 30 min, followed immediately by an
additional centrifugation step. Fixed cells were then resuspended in 500 µl of RPMI 1640. Ten
µl of cell solution was transferred to standard microscope slides, mounted with Prolong Antifade
Reagent, and sealed with 13 mm x13 mm pieces of cover glass.

2. 4. 3 Immunostain: CD25 on Lymphocytes and LAK Cells
Lymphocytes/LAK cells were adjusted to 5 x 106 cells/ml in RPMI 1640, in 5 ml falcon tubes.
Ten µl of CD25 specific monoclonal antibody (Clone 2A3; BD Biosciences, San Jose, CA)
or isotypic control (IgG1; Beckman Coulter) was added to the cell suspension, and allowed to
incubate for 30 min at room temperature. Equivalent concentrations/volumes of primary
antibody and control were used (5 µg/µl). Following incubation, tubes were centrifuged at 200 x
g for 10 min. The supernatant was discarded and subsequently 0.5 µL of secondary antibody
(Oregon Green labeled, mouse-anti-human; Beckman Coulter) was added to 1 milliliter of RPMI
1640, which was added to the pellet and incubated at room temperature for 30 min. The cells
were again washed via centrifugation at 200 x g for 10 min. The supernatant was discarded and
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the cells were resuspended in 500 µL of RPMI 1640. Cells were then fixed with 1 milliliter of
1% PFA in falcon tubes for 30 min, followed immediately by an additional centrifugation. The
pellet was resuspended in RPMI 1640 and 10 µL of cell solution was then transferred to standard
microscope slides, mounted with Prolong Antifade Reagent, and sealed with 13mm x13mm
pieces of cover glass.

2. 5 Preparation of SFn and Its Components, Fluorescent Probes, and Peptides
2. 5. 1 Preparation of Fibrinogen
Human, plasma derived fibrinogen (plasminogen-, fibronectin-, and factor XIII free) was
obtained from American Diagnostica Inc. (Greenwich, Connecticut). The lyophilized stock
amount (5 mg) was reconstituted in 2 ml of sterile deionized H2O, and allowed to sit at room
temperature for approximately 10 min while gently mixing solution to fully dissolve the reagent.
Aliquots (25, 50, and 100 µl) of stock fibrinogen were stored in cryo-safe tubes and kept at -80ºC
until time of experiment.

2. 5. 2 Preparation of Gly-Pro-Arg-Pro
The fibrin polymerization inhibitor Gly-Pro-Arg-Pro-amide (24 mM; GPRP-NH2) was obtained
from Sigma Chemical Company (St. Louis, MO). The lyophilized stock amount (5 mg) was
reconstituted in 2 ml of sterile, deionized H2O, and allowed to sit at room temperature for
approximately 10 min while gently mixing solution to fully dissolve the reagent. Aliquots (42
and 84 µl) of stock GPRP were stored in cryosafe tubes and kept at -80ºC until time of
experiment.
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2. 5. 3 Preparation of Thrombin
Thrombin (100 U/ml) was obtained from Sigma Chemical Company. The lyophilized stock
amount (5 mg) was reconstituted in 2 ml of sterile, deionized H2O, allowed to sit at room
temperature for approximately 10 min while gently mixing solution to fully dissolve the reagent.
Aliquots (5 and 10 µl) of stock thrombin were stored in cryo-safe vials and kept at -80º until time
of experiment.

2. 5. 4 Preparation of Soluble Fibrin
SFn is made in the required amount for each experiment. All component reagents were briefly
thawed to room temperature. To make one milliliter of sFn solution, 50 μl fibrinogen (0.5
mg/ml), 84 μl (4 mM) of GPRP-NH2, followed by 1.25 μl of thrombin were added to 865 μl of
RPMI 1640 in a sterile, 5 ml falcon tube. This solution was allowed to sit at room temperature
for 30 min to form sFn.

2. 5. 5 Preparation of Fluorescent Probes
Prepackaged, lyophilized probes, 1,1’-dioctadecyl-3,3,3’,3’-tetra-methylindocarbocyanine
perchlorate, or DiI (fluoresces red) and Calcein AM (fluoresces green), were obtained from
Invitrogen (Eugene, OR). Each probe was reconstituted in 50 µl of sterile DMSO (Sigma)
according to manufacturer recommendations (Akeson, 1993; Gant, 1992).

2. 5. 6 Preparation of Stock Peptides
Lyophilized peptides (50% purity) were obtained from Sigma-Genoysys (The Woodlands, TX).
Reconstitution was performed according to the manufacturer recommendations for each.
Peptides 1, 2, and 4 (designated in previous sections) were each made up to a 100 µM stock
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concentration in sterile PBS. Peptide 3 was first solubilized in a small amount of DMSO (on
account of its hydrophobicity), followed by subsequent suspension in PBS, and was made up to a
100 µM stock concentration. All peptides were divided into 50 µl aliquots, and stored at -20°C.

2. 6 Oregon Green Labeling of Effector Cells
EC, lymphocytes, and LAK cells were labeled with fluorescently labeled sFn and viewed
microscopically.

2. 6. 1 Preparation of Oregon Green Labeled SFn
Oregon Green labeled fibrinogen was obtained from Molecular Probes (Oregon Green 488 human
fibrinogen conjugate). Lyophilized stock fibrinogen (5 mg) was made up in RPMI 1640 to a total
volume of 5 ml, aliquotted into cryovials (25 µl each), and stored at -20°C. At time of
experiment, fluorescent sFn monomer (one milliliter) was made by thawing and adding 50 μl of
Oregon Green labeled fibrinogen, 84 μl of the fibrin polymerization inhibitor GPRP (24 mM),
followed by 1.25 μl thrombin (100 U/ml) to 865 μl of RPMI 1640 in a 5 ml falcon tube. This
solution was incubated at room temperature for 30 min prior to use in assay.

2. 6. 2 Preparation of Effector Cells
Lymphocytes, LAK cells, and EC were all cultured and isolated as discussed in previous sections,
counted to 5.0 x 106 cells per ml, and centrifuged at 200 x g for 10 min to obtain pellets. One ml
of prepared, fluorescently labeled sFn was added to each cell type, and allowed to incubate for 30
min in a 37ºC, 5% CO2 incubator. Ten µL of each cell type was added to a microscope slide,
covered with Prolong Antifade Reagent, and sealed with a 13 x 13 mm coverslip for microscopy.
Remaining cell suspensions were again centrifuged at 200 x g for 10 min, supernatants were
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discarded, and 500 µl of RPMI 1640 added to each. Slides were again prepared as previously
described.

2. 6. 3 Fluorescence Microscopy
An Olympus BX61 was used (100× oil immersion objective) to observe samples and Applied
Spectral Imaging Software (Vista, CA) was used to capture images. Using the same microscope
settings to observe differences in fluorescence between samples, five representative fields were
captured of each slide for each pretreatment. Images were processed using Image Pro Plus™,
Version 5.1, (Media Cybernetics, Silver Spring, MD) and deconvolved using AutoDeblur™
deconvolution software (Media Cybernetics).

2. 7 Binding of Lymphocytes and LAK Cells to Endothelial Cells Under Flow Conditions
2. 7 1 Preparation of Endothelial Cells on 40 mm Coverslips
Round, 40 mm coverslips were purchased from Bioptechs Inc. (Butler, PA). Coverslips were
sterilized using a pure grade ethanol wash. HMEC-1 cells were prepared in media as described
previously and counted to 1 x 106 cell/ml in DMEM with 10% FBS. One ml of cells, plus 4
additional ml of DMEM with 10% FBS was added to each sterile coverslip, in small Petri dishes.
Coverslips were incubated in a 37ºC, 5% CO2 incubator, for 24-48 hours, or until confluent.
Confluence was checked using an inverted, phase-contrast Zeiss microscope.

2. 7. 2 Preparation of Fluorescently Labeled Lymphocytes
Lymphocytes and LAK cells were isolated as described in previous sections. Lymphocytes were
labeled with 5 µl of DiI for 20 min at room temperature, centrifuged at 200 x g for 10 min to
remove excess probe, and the supernatant decanted from the labeled cells.
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2. 7. 3 Pretreatment of Effector Cells
Fluorescently labeled lymphocytes were suspended in 5 ml falcon tubes, (1 x 106 cells/ml each in
RPMI 1640 with 10% FBS), and confluent HMEC-1 cells grown on coverslips were removed
from incubators for experimentation. Cells were pretreated with sFn, peptides, or both as
described below.

2. 7. 3. 1 Pretreatment of Effector Cells with SFn (and Components)
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes (by
centrifugation) and EC (by manual pipet), respectively. One milliliter of sFn solution, Fg, GPRP,
or Thr was added to lymphocytes in tubes, and/or to EC on coverslips. All cells were incubated
at 37ºC, with 5% CO2 for 30 min prior to inclusion in assays.

2. 7. 3. 2 Pretreatment of Effector Cells with Peptides Prior to SFn
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes (by
centrifugation) and EC (by manual pipet), respectively. Cells were reconstituted in 1 ml peptide
solutions; EC with P1 and P3 (4 mM) and lymphocytes with P2 and P4 (4 mM) for 30 min,
followed by treatment with sFn for another 30 min, and incubated at 37ºC, with 5% CO2.

2. 7. 4 Assembly of FCS2 Closed Perfusion System
Figure 2-1 above shows a detailed setup of the FCS2 apparatus. Coverslips with a confluent
HMEC-1 cells were loaded into the FCS2 stage incubator (Bioptechs Inc.) and mounted on the
stage of a Leica DMIRB inverted fluorescence microscope equipped with a Hamamatsu Color
Chilled 3CCD camera (C5810 model) attached to a computer for data acquisition. A fluid
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pathway was formed (Dimensions 0.5 mm × 14 mm × 25 mm) by separating the microaqueduct
slide from the coverslip containing cells with a single silicone gasket with a rectangular bore,
generating near-laminar flow conditions during perfusion. The stage incubator was initially
connected to a peristaltic pump on the afferent side using 0.062 inch bore S/P medical grade
silicone tubing (Fisher Scientific, Suwanee, GA). The efferent side was connected to waste
initially. After connection of the electronic temperature control, the coverslips were perfused with
RPMI 1640 to briefly buffer the cells at 37°C for ten min. The flow rate was set to 0.5 ml/min,
which corresponds to a shear rate of 132.9 s-1, which falls between the reported range as earlier
discussed. The inlet was then connected to the tube containing the appropriately treated
lymphocyte suspension (3 ml total). The efferent tubing was also transferred back to the same
tube, and Di-I labeled lymphocytes were recirculated across the EC for 1 h, after which, the
tubing was set up to the initial configuration and the cells were again washed with RPMI for 10
more min to remove unbound lymphocytes.

2. 7. 5 Image Capture and Quantitative Analysis
Individual still images in five randomly chosen fields of view were captured at 10 x
magnification and stored on the computer. Image Pro Plus 5.1 software was used to quantitate the
number of lymphocytes (labeled red) that were bound in each of the captured images. Software
automatically selected for all fluorescent pixels present in each image, which separated the
fluorescent lymphocytes from the black background. The counts for each treatment were
manually added to a running spreadsheet (Microsoft Excel) for all experiments.
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2. 8 Endothelial Transmigration Assay
2. 8. 1 Preparation of Polycarbonate Inserts
Corning Polycarbonate Transwell Permeable Supports (8 µm pore size; 6.5 mm insert diameter;
0.33 cm2 growth area; 10 µm membrane thickness) were prepared in sterile, flat-bottomed 24well microtiter plates (Fisher Scientific). HMEC-1 cells were detached from tissue culture flasks
as previously described and counted to 1 x 106 cells/ml. 200 µl of this cell suspension
(containing 2 x105 cells) were added to the top well of the inserts and grown for approximately 48
hours at 37ºC with 5% CO2 conditions.

After cells were grown to probable confluence (approximately 48 h), a single representative insert
was labeled with 2 µl of stock fluorescent probe Calcein AM for 20 min at room temperature.
After incubation, the insert was gently washed with a sterile pipette three times with fresh DMEM
media to remove excess probe, and fluorescence microscopy was performed, using an inverted
Leica DMIRBE, with a 10x objective, to determine whether culture had grown to approximately
90%+ confluence for continuance of assay (using 488nm excitation; 535nm emission). Figure 2-3
is a representative image of a fluorescently labeled insert.

Figure 2-3 Calcein AM labeled HMEC-1 endothelial cells grown on polycarbonate inserts.
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2. 8. 2 Preparation of Tumor Cells in 24-well Plates
The cell line A375 (1 x 105 cells/well) was grown on the bottom of 24-well tissue culture-treated
microplates at 37ºC with 5% CO2 conditions for approximately 24 hours, or until confluence.

2. 8. 3 Preparation of Tumor Cell Conditioned Media (TCCM)
A375 cell cultures were grown to approximately 75-80% confluence, media aspirated, cells rinsed
with 5 ml of PBS, and incubated in 10 ml of fresh, serum free, RPMI 1640 for approximately 24
hours at 37°C/5% CO2. After 24 hours, the media were collected and subjected to centrifugation
(200 x g, 10 min) to remove debris, concentrated, and transferred to sterile, 15 ml conical tubes
until time of experiment.

2. 8. 4 Preparation of eACA
6-Aminohexanoic acid (eACA) is a lysine analog that promotes rapid dissociation of plasmin
from cells, which inhibits the activation of plasminogen and subsequent fibrinolysis.
Furthermore, EACA has been used to inhibit fibrin degradation by cells. Therefore, this reagent
was used during some experiments along with sFn in order to study its effect on diapedesis over
an 18 hour incubation period.
Stock concentration of eACA (Sigma) was made up to 400 mM in RPMI 1640. 50 µL of stock
solution was added to 1ml of sFn total solution, for a working concentration of 20 mM.

2. 8. 5 Preparation of Effector Cells for Transmigration Assays
Lymphocytes and LAK cells were isolated and labeled, and EC were isolated and seeded on
inserts as previously described in previous sections. Cells were then pretreated with sFn (and
components), peptides, or both as described below.
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2. 8. 6 Pretreatment with Soluble Fibrin and Components
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes and
LAK cells (by centrifugation at 200 x g) and EC (by manual pipet), respectively. SFn was
prepared as described earlier, and the 1 milliliter solutions of sFn, Fg, GPRP, or Thr was added to
lymphocytes in 5 ml falcon tubes, and/or to EC on coverslips. All cells were incubated at 37ºC,
with 5% CO2 for 30 min prior to inclusion in assays.

2. 8. 7 Pretreatment with Peptides Prior to Soluble Fibrin
RPMI 1640 with 10% FBS and DMEM with 10% FBS were removed from lymphocytes and
LAK cells (by centrifugation at 200 x g) and EC (by manual pipet), respectively. Cells were then
reconstituted in one ml of peptide solution (40 µl of each peptide in pair with 920 µl RPMI;4 mM
concentration each). EC were pretreated with P1 and P3 and lymphocytes with P2 and P4 for 30
min, followed by treatment with sFn (one milliliter total) for another 30 min, and incubated at
37ºC, with 5% CO2.

2. 8. 8 Transmigration Assay Setup
Having completed all experimental preparation as described in the previous sections, the assay
could be assembled as described below. The 24-well plate (containing the pretreated, confluent
endothelial monolayers grown on inserts), was removed from incubation, and the excess DMEM
present in the inserts was gently extracted using a 200 µl pipette and sterile tips. Inserts were
gently washed with DMEM using the same method. Two hundred µl (containing 2.0 x 105) of
lymphocytes or LAK cells (either untreated, or pretreated in sFn, Fg, GPRP, Thr, or peptides)
were added to the top of the appropriate pretreated insert. Another 24-well plate was prepared to
contain 600 µl of tumor cell conditioned media (TCCM) (or A375 cells in media) in the
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appropriate wells (to match the number of inserts being tested). The inserts were then transferred
from the original microplate to the new one with the media. All appropriate controls, including a
total (maximal lymphocyte migration; 2 x 105 cells), TCCM, and RPMI 1640 media controls
were also performed. Assays were incubated overnight at 37ºC, with 5% C02 for approximately
18 hours.

2. 8. 9 Transmigration Assay Quantitation
Following 18 hours of incubation, all inserts were gently removed (as to avoid any spilling from
the insert into the well below) from the 24-well microplate. The remaining TCCM solution,
containing the fluorescently labeled lymphocytes/LAK cells that have migrated through the
endothelial cell monolayer/polycarbonate membrane was measured by a Perkin Elmer Victor 3
microplate reader equipped for fluorescence. The plate reader was set up to excite with a filter
specific for excitation at 535 nm, and to emit with a 620 nm filter), to detect the DiI. The
excitation lamp was set to 40000, the aperture to normal width, and the capture time lapse to 1
second.

2. 9 Statistical Analysis Methods
2. 9. 1 Statistical Analysis of Adherence Assays
On a given day, I evaluated between 2 and 5 treatment conditions. For each treatment condition
performed, I obtained 5 fluorescent counts, taken from 5 randomly selected microscopy fields
(using Image Pro Plus software to quantitate), and averaged these into a single fluorescence data
point for that day. All data were stored on a running spreadsheet (in Microsoft Excel) until
completion of all experiments.
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Using JMP statistical software package (Cary, NC), paired sample t-tests (α=0.05) were
performed on all relevant treatment combinations. This test looks at differences between two
treatments each day the pair of treatments was performed (n = 3-15 days; depending on the pair).
Two-sided student’s t-tests were performed on all pairs because of uncertain expectations of
results. Student’s t-tests provide some useful information about these studies. However, their
application is somewhat limited here, because of the low number of degrees of freedom (DF) for
certain treatment pairs. In order to overcome this low DF, and provide additional analyses of
each experimental setup, models were fit using JMP statistical software.

If we are willing to assume error variances are equal for the treatments, then a model can be fit to
include additional data from other days of experimentation. Table 2.1 (A) is a representative data
set that was modeled in JMP to calculate Least Square Means (LSM’s), which estimates new
averages (LSM’s) assuming each treatment appeared on all dates. The LSM values for those
treatments that have been performed all days (+/+ and -/-) will be the same as the standard means
that were calculated for these same treatment (highlighted in blue; Table 2-1 A,B). However, the
means of those treatments that were only performed on some days (+/- and -/+) were adjusted (in
either an upward or downward direction) to project an LSM value for these treatments
(highlighted in red; Table 2-1 (B)). The amount and direction in which these values are adjusted
is dependent upon the original measurements obtained.

Also using JMP, Tukey’s multiple comparisons tests were performed on all models (on LSM’s)
to control the overall risk for Type 1 errors, i.e. to control the risk of falsely declaring differences
between treatments. This test also identifies significant differences between treatments, but does
not always correspond with original t-tests results, due to the inclusion of different values.
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Table 2-1 Computation of Least Square Means for models
A) Representative data set for fitting Least Square Means

2/8/2007
2/15/2007
2/18/2007
2/22/2007
2/24/2007
2/27/2007
2/28/2007
3/1/2007
3/2/2007
3/6/2007
3/8/2007
3/10/2007
3/28/2007
3/30/2007
4/2/2007
Mean
St Dev

(-/-)
3519
3453
3497
3811
4658
4094
4833
5171
3586
4359
3889
3002
3220
3678
3192
3864.13
639.36

(+/+)
1131
1841
1428
2001
1867
2043
1564
1465
1433
2779
1470
1272
1733
2214
1938
1745.27
421.76

(-/+)
.
.
.
3050
3038
.
.
.
.
.
.
.
.
2374
.
2820.67
386.87

(+/-)
.
2382
2508
.
.
.
.
.
.
.
.
.
.
2578
.
2489.33
99.32

B) Representative Least Square Means table
Level
Mean (-/-)
Mean (-/+)
Mean (+/-)
Mean (+/+)

Least Sq Mean
3864.13
2597.91
2645.79
1745.27

Std Error
115.95
302.47
302.47
115.95

Mean
3864.13
2820.67
2489.33
1745.27
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2. 9. 2 Statistical Analysis of Lymphocyte Transendothelial Migration Assays
On a given day, I evaluated between 4 and 8 different treatment conditions. I obtained one data
point from each insert prepared, in arbitrary fluorescence units provided by plate reader software
(depending on set parameters). When multiple inserts (2) of the same treatment were performed
in a day (all experiments except optimization assays), individual data points of the same treatment
were then combined (added) to obtain a mean and standard deviation of each treatment for that
day. A total fluorescence measurement and a tissue culture conditioned media (TCCM) control
were also performed each day. The mean of the TCCM measurement for each day was
subtracted from all other treatments (to control out “background” from each measurement).

Using JMP software, matched pair student’s t-tests (one or two-sided) were performed on
appropriate pairs to determine any significant differences of fluorescence (migration) between
treatments.

Similar statistical methods were employed as previously described for the binding section above.
If we are willing to assume error variances are equal for the treatments, then a model can be fit to
include additional data from other days of treatment. LSMs were computed assuming all
treatments appeared on all dates. Also using JMP, Tukey’s multiple comparisons tests were
performed on all models to control the overall risk for Type 1 errors.
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CHAPTER 3. RESULTS
3. 1 Cellular Immunostaining
3. 1. 1. von Willebrand’s Factor on HMEC-1 Cells
HMEC-1 cells were immunostained for human factor VIII/V or von Willebrand’s Factor (using
specific monoclonal antibody directed against vWF, and a fluorescently labeled secondary
antibody) showed significant expression of this cellular molecule (Figure 3-1) compared to the
purified immunoglobulin matched isotypic control (IgG1). Furthermore, nonlabeled cells and a
secondary antibody control were also performed (indicating no autofluorescence, and almost no
nonspecific binding of secondary antibody, respectively). This signifies that HMEC-1 cells
contain the storage organelles (Weibel-Palade Bodies), which contain key components of both
inflammatory and haemostatic processes (vWF secretion).

3. 1. 2 CD54 on HMEC-1 Cells
HMEC-1 cells immunostained for CD54 showed significant expression of this cellular receptor
(Figure 3-2) compared to the purified immunoglobulin matched isotypic control (IgG1) indicating
almost no nonspecific labeling. This corresponds with reports that this particular cell line (which
is representative of many vascular EC in vivo) that express this receptor.

3. 1. 3 CD25 on Lymphocytes and LAK Cells
Lymphocytes and LAK cells immunostained for CD25, both showed increased expression of this
cellular molecule (Figure 3-4) compared to its purified immunoglobulin matched isotypic control
(IgG1). However, as expected, LAK cell signal fluorescence (or fluorescence intensity) was
higher than that of untreated lymphocytes.
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Figure 3-1. vWF expression on HMEC-1 endothelial cells.
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Figure 3-2. CD54 expression on HMEC-1 endothelial cells.
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Figure 3-3 CD25 expression on lymphocytes (A) and LAK cells (B)

3. 2 Oregon Green Labeled SFn Pretreatment of LAK and Endothelial Cells
LAK cells and EC were incubated alone or in the presence of fluorescently labeled sFn. Figure 34 shows considerable binding of sFn to both LAK cells (A) and EC (B.), whereas no fluorescence
was observed on cells incubated in the absence of sFn.

3. 3 Lymphocyte and LAK Cell Adherence to Endothelial Cells Under Flow Conditions
To simulate the fluid shear stresses present in vivo, lymphocytes or LAK cells were perfused
across coverslips containing adherent HMEC-1 cells that were loaded into the FCS2 stage
incubator, and mounted on the stage of an inverted fluorescence microscope equipped with a
camera attached to a computer for data acquisition. Figure 3-5 is a representative image of
fluorescently labeled lymphocytes that adhered to EC which was analyzed for quantitation.
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Figure 3.4 Oregon Green labeled sFn binding to LAK cells (A) and endothelial cells (B).
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Figure 3-5 DiI labeled lymphocytes adherent to EC for fluorescence quantitation
by Image Pro Plus software

3. 3. 1 Lymphocyte Adherence to Endothelial Cells in the Presence of Soluble Fibrin
SFn pretreatment of one or both cell types (EC/lymphocytes, respectively) significantly affected
the binding events observed under flow conditions. Figure 3-6 shows the mean fluorescence
units measured for each treatment (as determined by IPP software). Means for each day are listed
in Table A-1 in the appendix. Untreated cells of each type (-/-) were used as a control value of
the maximum number of fluorescence units measured for each experiment. Each other
pretreatment measurement was then tested against the untreated control value in order to calculate
percent inhibition of adherence. Furthermore, standard deviations for each pretreatment were
further calculated including only those days that the treatment of interest was performed.
Pretreatment of both cell types with sFn (+/+), resulted in the fewest number of bound
lymphocytes to EC (or least fluorescence observed), resulting in a mean ± standard deviation of
54.1 ± 11.3% inhibition when compared to the control (n=15). Pretreatment of only EC (+/-)
resulted in a 29.7 ± 1.4% decrease of binding events (n=3). Similarly, pretreatment of
lymphocytes only (-/+) resulted in a 30.1 ± 8.8 % decrease of fluorescence (n=3).
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Figure 3-6. Effect of sFn pretreatment on lymphocyte adherence to endothelial cells (endothelial
cells and lymphocytes, respectively) under flow conditions. All measurements are presented as
percent inhibition compared to untreated cells. Values were produced by quantitation of
adherent, fluorescently labeled lymphocytes to endothelial cells using Image Pro Plus software
package.
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3. 3. 2 Statistical Analysis: Lymphocyte Binding to Endothelial Cells in the Presence of
Soluble Fibrin
Using JMP, matched pair student t-tests (α=0.05; Table A-2) were performed on the original data
for the four possible pretreatment combinations of sFn (-/-, +/+, -/+, +/-). When neither cell type
was pretreated with sFn (-/-), the mean fluorescence measured (binding events) was significantly
larger than all other treatment means (+/+, +/-, and -/+). Furthermore, there were no additional
significant differences found between any of the other treatment combinations.

Also using JMP, an additive model, including terms for date (15 days) and treatment (4 levels),
was fit using Standard Least Squares. I obtained an R2 value of 0.91 (Table 3-1; Part A), with
treatment differences explaining the vast majority of the variation of fluorescence measurements.
The Root Mean Square Error of 449.1 estimates the assumed standard deviation. The mean of
response, and total observations are also listed.

Furthermore, the analysis of variance (ANOVA) (Table 3-1; Part B) provided an F ratio of
11.3324 (P <.0001) indicating a significant model. The model accounts for approximately 91%
of variation (from R2 value), whereas the unexplained variation accounts for the other 9%.

The residuals were also examined, and they were consistent with our assumption of a common
variance. There are no “extreme outliers” that need additional attention for this model (Table 3-1;
Part C).
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Table 3-1. Statistical analysis: lymphocyte adherence to endothelial cells in the presence of
soluble fibrin.
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.914551
449.061
2779.744
36

B) Analysis of Variance
Source
Model
Error
C. Total

DF
17
18
35

Sum of Squares
38849167
3629805
42478971

Mean Square
2285245
201656

F Ratio
11.3324
Prob > F
<.0001

C) Residual by Predicted Plot

Mean Residual

1000
500
0
-500
-1000
1000 2000

3000

4000

5000

Mean Predicted

D) Effect Tests
Source
Date
Treatment

Nparm
14
3

DF
14
3

Sum of Squares
4903330
33794276

F Ratio
1.7368
55.8613

Prob > F
0.1345
<.0001

E) Least Squares Means Table
Level
Mean (-/-)
Mean (-/+)
Mean (+/-)
Mean (+/+)

Least Sq Mean
3864.0933
2597.9093
2645.7950
1745.3200

Std Error
115.94706
302.46841
302.46841
115.94706

Mean
3864.09
2820.60
2489.27
1745.32
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The Effect Tests Table (Table 3-1; Part D) indicates that the date (DF=14) of the experiment was
found to be an insignificant factor (P=0.1345; F Ratio=1.7638). However, pretreatment (DF=3)
was found to be a significant factor (P < .0001; F Ratio=55.86).

Table 3-1, Part E is the Least Square Means table that was generated using this model.
Furthermore, the specific LSM value is included for each, followed by the computed standard
error and the simple mean computation. Note that both the LSM and mean are the same for both
treatments (-/- and +/+) that were performed all days. However, the LSM value for (-/+) has been
adjusted in a downward (negative) direction, and the LSM for (+/-) has been adjusted in an
upward (positive) direction. This is due to fact that those days that (-/+) and (+/-) were tested, the
(-/-) and (+/+) pretreatment measurements tended to be higher and lower (respectively) than other
days.

Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 3-2
includes the specific details for each sFn pretreatment, including the lower and upper bounds
(confidence intervals) with 95% certainty (CL Dif). Those values that are in red correspond to
significant differences in the model.

Using this method, it was again shown that when neither cell was pretreated (-/-), the average
fluorescence measured was significantly different than all other pretreatments involving sFn.
However, when both cell types were treated with sFn (+/+) was not significantly different than
other intermediate treatments’ fluorescence. Furthermore, the intermediate treatments’
measurements were not significantly different than one another. Table 3-2 (B) is a summary of
these results.
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Table 3-2. LSM differences Tukey’s multiple comparison method: Lymphocyte adherence to
endothelial cells in the presence of soluble fibrin. Those columns in red are significant.
A) LSMeans differences Tukey’s table. α=0.050; Q=2.82629.
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
Mean (-/-)

Mean (-/+)

Mean (+/-)

Mean (+/+)

Mean (-/-)

Mean (-/+)

Mean (+/-)

Mean (+/+)

0
0
0
0
-1266.2
323.93
-2181.7
-350.66
-1218.3
323.93
-2133.8
-302.78
-2118.8
163.974
-2582.2
-1655.3

1266.18
323.93
350.663
2181.71
0
0
0
0
47.8857
415.75
-1127.1
1222.92
-852.59
323.93
-1768.1
62.9323

1218.3
323.93
302.777
2133.82
-47.886
415.75
-1222.9
1127.14
0
0
0
0
-900.47
323.93
-1816
15.0466

2118.77
163.974
1655.34
2582.21
852.589
323.93
-62.932
1768.11
900.475
323.93
-15.047
1816
0
0
0
0

B) Tukey’s summary. Levels not connected by same letter are significantly different.
Level
Mean (-/-)
Mean (+/-)
Mean (-/+)
Mean (+/+)

A
B
B
B

Least Sq Mean
3864.0933
2645.7950
2597.9093
1745.3200

64

3. 3. 3 Lymphocyte Adherence to Endothelial Cells in the Presence of Fibrinogen, GPRP,
and Thrombin
Untreated cells of each type (-/-) were used as a control value to obtain the maximum
fluorescence (binding) measured (n = 15). Figure 3-7 shows the mean fluorescence units
measured for each treatment (as determined by IPP software). Pretreatment of both cell types
with sFn (+/+) resulted in the fewest number of bound lymphocytes to EC, resulting in a 54.1 ±
11.3% inhibition of fluorescence when compared to the control. Cells pretreated with fibrinogen
resulted in a 6.8 ± 10.30% inhibition of binding events (n = 3). Cells pretreated with GPRP
resulted in a 5.1 ± 3.3% decrease of binding events (n = 3). And when both cells were pretreated
with thrombin, fluorescence was only decreased by 4.0 ± 5.8% (n=3). Means for each treatment
combination for each day of experimentation are presented in Table A-1 in the appendix.

3. 3. 4 Statistical Analysis: Lymphocyte Adherence to Endothelial Cells in the Presence of
Fibrinogen, GPRP, and Thrombin
Using JMP, matched pair student t-tests (α = 0.05) were performed on the original data for
appropriate pairs of the five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP,
Thr/Thr). Individual tests for all appropriate tests are listed in Table A- 2 in the appendix. When
both cell types were pretreated with sFn (+/+), the mean fluorescence measured was significantly
different than all other treatments performed (-/-, Fg,Fg, Thr/Thr, GPRP/GPRP). Furthermore,
there were no additional significant differences found between any of the other treatment
combinations (Table A-2).

Also using JMP, an additive model, including terms for date (15 days) and treatment (5 levels),
was fit using Standard Least Squares. I obtained an R2 value of 0.92 (Table 3-3 (A)), with
65

70
60

% Inhibition

50
40
30
20
10

/G
PR

G
P

R
P

Th
r /T
hr

P

g
Fg
/F

+/
+

0

Pretreatment

Figure 3-7. Effect of soluble fibrin components (fibrinogen, GPRP, and thrombin individually)
on lymphocyte adherence to endothelial cells under flow conditions. All measurements are
presented as percent inhibition compared to untreated cells. Values were produced by
quantitation of adherent, fluorescently labeled lymphocytes to endothelial cells using Image Pro
Plus software package.
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Table 3-3. Statistical analysis: lymphocyte adherence to endothelial cells in the presence of
fibrinogen, GPRP, and thrombin.
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.920619
440.6393
3003.533
39

B) Analysis of Variance
Source
Model
Error
C. Total

DF
18
20
38

Sum of Squares
45035802
3883260
48919062

Mean Square
2501989
194163

F Ratio
12.8860
Prob > F
<.0001

C) Residual by Predicted Plot

Data Residual

1000
500
0
-500
-1000
1000 2000

3000

4000

5000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
14
4

DF
14
4

Sum of Squares
6184911
35002211

F Ratio
2.2753
45.0681

Prob > F
0.0455
<.0001

E) Least Squares Means Table
Level
Mean(Fg/Fg)
Mean(GPRP/GPRP)
Mean(-/-)
Mean(+/+)
Mean(Thr/Thr)

Least Sq Mean
3312.8067
3417.7400
3864.0933
1745.3200
3479.7400

Std Error
301.01394
301.01394
113.77258
113.77258
301.01394

Mean
3575.67
3680.60
3864.09
1745.32
3742.60
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treatment differences explaining the majority of the variation of fluorescence. The Root Mean
Square Error of 440.6 estimates the assumed common standard deviation. The mean response
and total observations (39) are also listed.

Furthermore, the ANOVA (Table 3-3 (B)) provided an F ratio of 12.89 (P <.0001), indicating a
significant model. This model accounts for approximately 92% of variation (from R2 value),
whereas the unexplained variation accounts for the remaining 8%.

The residuals for the model were also examined, and they were consistent with the assumption of
a common variance. There are no “extreme outliers” that need additional attention for this model
(Table 3-3 (C)).

The Effect Tests Table (Table 3-3 (D)) indicates that the date (DF=14) of the experiment was
found to be a significant factor (P=0.046; F Ratio=2.28). This could be due to the fact that
different aliquots of reagents (blood, soluble fibrin, EC, probes, etc.) are used daily, which could
influence final results. Pretreatment (DF=4) was also found to be a significant factor (P < .0001;
F Ratio=45.07).

Table 3-3 (E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for both
treatments (-/- and +/+) because they were performed all days. However, the LSM value for all
other treatments (Fg/Fg, GPRP/GPRP, Thr/Thr) have all been adjusted in a downward (negative)
direction. This is due to fact that those days that these treatments were tested, the fluorescence
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measurements tended to be higher than for the other days.

Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all
pairs of the five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP, Thr/Thr).
Table 3-4 (A) includes the specific details for each sFn component pretreatment, including the
lower and upper bounds with 95% certainty (CL Dif). Those columns that are in red correspond
to those values that are significant in the model. Furthermore, Table 3-4 (B) is a summary of
these results. When pretreating both cell types with sFn (+/+), the average fluorescence
measurement was significantly different than all other pretreatments. None of these controls’
average fluorescence measurements were found to be significantly different than when neither
cell type (-/-) was pretreated. Furthermore, there were no additional significant differences found
between any of the other treatment combinations.

3. 3. 5 Lymphocyte Adherence to Endothelial Cells in the Presence Peptides and SFn
SFn pretreatment of one or both cell types significantly affected the binding events observed
under flow conditions. Figure 3-8 represents the mean fluorescence measurements for each
treatment performed. Untreated cells of each type (-/-) were used as a control value to determine
maximum fluorescence measured (n=15). Pretreatment of both cell types with sFn (+/+) resulted
in the fewest number of bound lymphocytes to EC (or least fluorescence observed), resulting in a
54.1 ± 11.3 % inhibition when compared to the control (n=3). EC and lymphocytes that were
treated with both peptides 1 and 3 (P1/P3), prior to sFn exposure, resulted in only a 26.7 ± 4.1%
inhibition of fluorescence, restoring some binding (n=3). However, EC and lymphocytes treated
with peptides 2 and 4 (P2/P4), prior to sFn exposure, resulted in only a 46.1 ± 12.3% inhibition of
fluorescence (n=3). Table A-1 in the appendix lists specific means for each day of experiments.
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Table 3-4. LSMs differences Tukey’s multiple comparison method (soluble fibrin components).
Those columns in red are significant.
A) LSMeans differences Tukey’s table. α=0.050; Q=2.99238.
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(+/+)

(-/-)

Fg/Fg

GPRP/GPRP

Thr/Thr

(+/+)

(-/-)

0
0
0
0
2118.87
160.89
1637.42
2600.31
1567.27
321.779
604.382
2530.15
1672.27
321.779
709.382
2635.15
1734.6
321.779
771.716
2697.48

-2118.9
160.89
-2600.3
-1637.4
0
0
0
0
-551.6
321.779
-1514.5
411.284
-446.6
321.779
-1409.5
516.284
-384.27
321.779
-1347.2
578.618

Fg/Fg GPRP/GPRP

-1567.3
321.779
-2530.2
-604.38
551.6
321.779
-411.28
1514.48
0
0
0
0
105
359.76
-971.54
1181.54
167.333
359.76
-909.2
1243.87

-1672.3
321.779
-2635.2
-709.38
446.6
321.779
-516.28
1409.48
-105
359.76
-1181.5
971.538
0
0
0
0
62.3333
359.76
-1014.2
1138.87

Thr/Thr

-1734.6
321.779
-2697.5
-771.72
384.267
321.779
-578.62
1347.15
-167.33
359.76
-1243.9
909.204
-62.333
359.76
-1138.9
1014.2
0
0
0
0

B) Summary of Tukey’s table. Levels not connected by same letter are significantly different.

Level
(-/-)
Thr/Thr
GPRP/GPRP
Fg/Fg
(+/+)

A
A
A
A
B

Least Sq Mean
3864.0933
3479.8667
3417.5333
3312.5333
1745.3200
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Figure 3-8. Effect of peptide and sFn pretreatment on lymphocyte adherence to endothelial cells
under flow conditions. All measurements are presented as percent inhibition compared to
untreated cells. Values were produced by quantitation of adherent, fluorescently labeled
lymphocytes to endothelial cells using Image Pro Plus software package.
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3. 3. 6 Statistical Analysis: Lymphocyte Adherence to Endothelial Cells in the Presence of
Peptides and Soluble Fibrin
Using JMP, matched pair student t-tests (α = 0.05) were performed on all possible pairs of the
original data for the four pretreatment combinations (-/-, +/+, P1/P3, and P2/P4). Specific t-test
values are listed in Table A- 2 in the appendix. When neither cell type was pretreated with sFn
(-/-), the mean fluorescence was significantly larger than when both cells were pretreated (+/+),
and larger than when cells were pretreated with peptides P2/P4 prior to sFn. However, when cells
were pretreated with P1/P3, prior to sFn, the mean fluorescence was found to be significantly
different than when neither cell was untreated (-/-). Pretreatment of both cells (+/+) was also
significantly different than pretreatment with peptides P1/P3.

Also using JMP, an additive model, including terms for date (15 days) and treatment (4 levels),
was fit using Standard Least Squares. An R2 value of 0.92 was obtained (Table 3-5 (A)), with
treatment differences explaining the majority of the variation within fluorescence. The Root
Mean Square Error of 447.2 estimates the assumed common standard deviation. The mean
response (fluorescence), and total observations (n=36) are also listed.

Furthermore, the ANOVA (Table 3-5; Part B) provided an F ratio of 12.60 (P <.0001), indicating
a significant model. This model accounts for approximately 92% of variation (from R2 value),
whereas the unexplained variation accounts for the remaining 8%.

The residuals were also examined, and they were consistent with our assumption of a common
variance. There are no “extreme outliers” that need additional attention for this model (Table 3-5
(C)).
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Table 3-5. Statistical analysis: lymphocyte adherence to endothelial cells in the presence of
peptides and soluble fibrin
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.922488
447.1762
2762.667
36

B) Analysis of Variance
Source
Model
Error
C. Total

DF
17
18
35

Sum of Squares
42837068
3599398
46436466

Mean Square
2519828
199967

F Ratio
12.6012
Prob > F
<.0001

C) Residual by Predicted Plot
1000

Data Residual

500

0

-500

-1000
1000

2000

3000

4000

5000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
14
3

DF
14
3

Sum of Squares
5434470
34650112

F Ratio
1.9412
57.7598

Prob > F
0.0929
<.0001

E) Least Squares Means Table
Level
(+/+)
(-/-)
P1/P3
P2/P4

Least Sq Mean
1745.2667
3864.1333
3102.7000
2172.0333

Std Error
115.46040
115.46040
305.47951
305.47951

Mean
1745.27
3864.13
3306.67
1798.33
73

The Effect Tests Table (Table 3-5 (D)) indicates that the date (DF=14) of the experiment was not
found to be a significant factor (P=0.093; F Ratio=1.94). Pretreatment (DF=3) was found to be a
significant factor (P < .0001; F Ratio=57.76).

Table 3-5 (E) is the Least Square Means table that was generated using this model. The specific
LSM value is included for each treatment, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for both
treatments (-/- and +/+) because they were performed all days. However, the LSM values for the
other treatments (P1/P3 and P2/P4)) have both been adjusted. P1/P3 has been adjusted in a
downward (negative) direction, and P2/P4 in an upward (positive) direction. This is due to fact
that those days that these treatments were tested, their fluorescence measurements tended to be
higher and lower, respectively, than projected for the other days.

Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all
pairs of the four possible pretreatment combinations (-/-, +/+, P1/P3, P2/P4). Table 3-6 (A)
includes the specific details for each pretreatment, including the lower and upper bounds with
95% certainty (CL Dif). Those columns that are in red correspond to those values that are found
to significant in the model. When neither cell type was pretreated (-/-), the average fluorescence
measurement was found to be significantly higher than when both cell types were pretreated with
sFn (+/+), and when pretreated with P2/P4 prior to exposure to sFn. However, when cells were
left untreated (-/-), the average fluorescence was not significantly different than pretreatment with
P1/P3 peptide pair. In addition, pretreatment of both cells (+/+) was significantly different than
treatment with P1/P3, however it was not significantly different than P2/P4 pretreatment
measurements according to this model. Table 3-6 (B) is a summary of these results.
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Table 3-6. LSM differences Tukey’s multiple comparisons method. Those columns in red are
significant.
A) LSMeans differences Tukey’s HSD. α=0.050; Q=2.82629.
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(+/+)

(-/-)

P1/P3

P2/P4

(+/+)

(-/-)

P1/P3

P2/P4

0
0
0
0
2118.87
163.286
1657.37
2580.36
1357.43
326.571
434.448
2280.42
426.767
326.571
-496.22
1349.75

-2118.9
163.286
-2580.4
-1657.4
0
0
0
0
-761.43
326.571
-1684.4
161.552
-1692.1
326.571
-2615.1
-769.11

-1357.4
326.571
-2280.4
-434.45
761.433
326.571
-161.55
1684.42
0
0
0
0
-930.67
447.176
-2194.5
333.184

-426.77
326.571
-1349.8
496.219
1692.1
326.571
769.114
2615.09
930.667
447.176
-333.18
2194.52
0
0
0
0

B) Summary of Tukey’s results. Levels not connected by same letter are significantly different.
Level
(-/-)
P1/P3
P2/P4
(+/+)

A
A B
B C
C

Least Sq Mean
3864.1333
3102.7000
2172.0333
1745.2667
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3. 3. 7 LAK Cell Adherence to Endothelial Cells in Presence of Soluble Fibrin and Peptides
SFn pretreatment of one or both cell types (endothelial/LAK cells, respectively) significantly
affected LAK cell binding to EC observed under flow conditions. Figure 3-9 shows the mean
fluorescence units measured for each treatment (-/-, +/+, P1/P3, P2/P4). Untreated cells of each
type (-/-) were used as a control value of maximum number of fluorescence units measured for
each experiment. Pretreatment of both cell types with sFn (+/+), resulted in the fewest number of
bound LAK cells to EC (least fluorescence observed), resulting in a 43.9 ± 4.4% inhibition when
compared to the control (n=2). Pretreatment of cells with peptides P1/P3 resulted in a 25.1 ± 6.2
% decrease of binding events (n=2), and pretreatment of cells with peptides P2/P4 resulted in a
37.05 ± 4.7% decrease of fluorescence (n=2). Specific measurements for each treatment are
listed in Table A-3 in the appendix.

3. 3. 8 Statistical Analysis: LAK Cell Adherence to Endothelial Cells Under In the Presence
of Soluble Fibrin and Peptides
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs for the four
pretreatment combinations (-/-, +/+, P1/P3, and P2/P4). All specific t-test results are listed in
Table A-4 in the appendix. When neither cell type was pretreated (-/-), the mean fluorescence
was not significantly greater than when both cells were pretreated (+/+), or when cells were
treated with P2/P4 or P1/P3 peptide pairs, prior to sFn. This result can be partially explained by
the low DF employed for the t-test for this comparison. However, when both cell types were
prestreated with sFn (+/+), the mean fluorescence was significantly different than pretreatment
with P1/P3 and P2/P4 peptide pairs. Finally, when cells were pretreated with either peptide pair,
the mean fluorescence was found to be significantly different than one another.
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Figure 3-9. Effect of soluble fibrin and peptides on LAK cell adherence to endothelial cells
under flow conditions. All measurements are presented as percent inhibition compared to
untreated cells. Values were produced by quantitation of adherent, fluorescently labeled
lymphocytes to endothelial cells using Image Pro Plus software package.
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Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels),
was fit using Standard Least Squares. I obtained an R2 value of 0.99 (Table 3-7 (A)), with
treatment differences explaining virtually all of the variation in fluorescence. The Root Mean
Square Error of 179.7 estimates the assumed common standard deviation. The mean of response
and total observations (8) are also listed.

Furthermore, the ANOVA (Table 3-7 (B)) provided an F ratio of 50.60 (P <.0044), indicating a
significant model. The model accounts for approximately 99% of variation (from R2 value),
whereas, those unexplained variation accounts for the remaining 1%.

The residuals were also examined, which were consistent with our assumption of common
variance. There are no “extreme outliers” that need additional attention for this model. (Table 3-7
(C)).

The Effect Tests Table (Table 3-7 (D) indicates that the date (DF=1) of the experiment was not
found to be a significant factor (P=0.68; F Ratio=0.21). Pretreatment (DF=3) was found to be a
significant factor (P < .0003; F Ratio=67.39).

Table 3-7 (E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for all
treatments because all combinations were performed all days included in the model.
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Table 3-7. Statistical analysis: LAK cell adherence to endothelial cells in the presence of soluble
fibrin and blocking peptides.
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.985394
179.656
3958.7
8

B) Analysis of Variance
Source
Model
Error
C. Total

DF
4
3
7

Sum of Squares
6532434.2
96828.9
6629263.1

Mean Square
1633109
32276

F Ratio
50.5978
Prob > F
0.0044

C) Residual by Predicted Plot

Data Residual

200
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Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
1
3

DF
1
3

Sum of Squares
6867.9
6525566.3

F Ratio
0.2128
67.3928

Prob > F
0.6760
0.0030

E) Least Squares Means Table
Level
(-/-)
(+/+)
P1/P3
P2/P4

Least Sq Mean
5392.4000
3021.6000
4031.2000
3389.6000

Std Error
127.03601
127.03601
127.03601
127.03601

Mean
5392.40
3021.60
4031.20
3389.60
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Tukey’s multiple comparison method (α = 0.05) was then performed on the LSM values, for all
pairs of the five possible pretreatment combinations (-/-, +/+, P1/P3, P2/P4). Table 3-8 (A)
includes the specific details for each pretreatment, including the lower and upper bounds with
95% certainty (CL Dif). Those columns that are in red correspond to those values that are
significant in the model. Table 3-8 (B) is a summary of these results. When neither cell type was
pretreated (-/-) with sFn, the average fluorescence was significantly larger than all other
treatments’ means. Furthermore, when both cell types were pretreated with sFn (+/+), the
average fluorescence was significantly different than when neither cell was treated with sFn (-/-),
and when pretreated with P1/P3 prior to exposure to sFn. Furthermore, when cells were
pretreated with the P1/P3 pair, the average fluorescence was not significantly different than P2/P4
pretreatment according to this model. Pretreatment with P2/P4 was significantly different than
when neither cell was pretreated, but not different than when both cell types were pretreated with
sFn.

3. 4 Lymphocyte Transendothelial Migration Optimization Assays
This section addresses the results of the transendothelial migration assays that were performed in
order to investigate the ability of lymphocytes and activated LAK cells to permeate through
confluent monolayers of EC grown on polycarbonate inserts under many different conditions.
Each section below reports a separate experiment using different methodology.

3. 4. 1 Effect of Tumor Cells and TCCM on Migration
Lymphocyte migration through EC was measured in the presence and absence of either A375
tumor cells grown in 24-well microplates, or tissue culture conditioned media (TCCM) solution.
A total count of fluorescence was also performed, including the maximum number of
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Table 3-8. LSM differences Tukey’s multiple comparisons method (peptides and soluble fibrin).
Those columns in red are significant.
A) LSMean[i] By LSMean[j]. α=0.050; Q=4.82567.

Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(-/-)

(+/+)

P1/P3

P2/P4

(-/-)

(+/+)

P1/P3

P2/P4

0
0
0
0
-2370.8
179.656
-3237.8
-1503.8
-1361.2
179.656
-2228.2
-494.24
-2002.8
179.656
-2869.8
-1135.8

2370.8
179.656
1503.84
3237.76
0
0
0
0
1009.6
179.656
142.638
1876.56
368
179.656
-498.96
1234.96

1361.2
179.656
494.238
2228.16
-1009.6
179.656
-1876.6
-142.64
0
0
0
0
-641.6
179.656
-1508.6
225.362

2002.8
179.656
1135.84
2869.76
-368
179.656
-1235
498.962
641.6
179.656
-225.36
1508.56
0
0
0
0

B) Summary of Tukey’s test. Levels not connected by same letter are significantly different.
Level
(-/-)
P1/P3
P2/P4
(+/+)

A
B
B C
C

Least Sq Mean
5392.4000
4031.2000
3389.6000
3021.6000

.
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lymphocytes (2 x 105 per well). Figure 3-10 shows all treatments that were performed as a
percentage of the total fluorescence count measured (100%). When lymphocytes were added to
those wells with A375 tumor cells grown in the plates, 95.3% fluorescence was observed after 18
hours of incubation with EC. When cells were incubated in the presence of one of two different
batches of A375 conditioned TCCM (TCCM 1 and TCCM 2), 83.2% and 85.5% fluorescence
was measured, respectively. In the absence of tumor cells or TCCM, cells incubated with RPMI
media instead, resulted in only 17.4% total fluorescence. Controls including A375 cells grown in
wells (39.9%), TCCM 1 (33.31%) and TCCM 2 (37.0%), and RPMI media alone (10.6%) were
also performed.

Since this setup was not replicated, no statistical analysis was performed. However it is clear
from Figure 3-10 that the presence of A375 tumor cells and TCCM derived from A375 tumor
cells acts as a chemoattactant toward the lymphocytes present in inserts (lymph/A375,
lymph/TCCM1, or lymph/TCCM2 versus the lymph/RPMI treatment). Additionally, the
background readings (A375, TCCM1, and TCCM2) were found to be comparable to one another,
but more than RPMI media alone.

Furthermore, an 18 hour assay was found to be appropriate, as the fluorescence observed from the
lymphocytes incubated with A375 cells grown in the microplate was quite similar to the total
(100%), which was one major goal of the exercise. Furthermore, both batches of
lymphocyte/TCCM exhibited a similar measurement to one another, and a comparable value as
compared to the total and the lymphocyte/A375 measurements. The other control measurements
(TCCM1, TCCM2, RPMI, and A375) all produced measurements less than half of all other
treatments.
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Figure 3-10. Effect of tumor cells and TCCM on total fluorescence observed.
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3. 4. 2 Effect of Various Concentrations of Fibrin(ogen)/Soluble Fibrin on Lymphocyte
Transendothelial Migration
Pretreatment with 4 different concentrations of sFn reagents (fibrinogen concentrations included
0.25, 0.50, 0.75, 1.0 mg/ml, with corresponding increases in GPRP and thrombin concentrations)
were performed. Figure 3-11 shows the corresponding levels of inhibition caused by
pretreatment with each. Pretreatment with 0.25 mg/ml of Fg (in sFn made with corresponding
levels of GPRP and thrombin) resulted in a 14.10 ± 6.11% inhibition compared to migration
observed of untreated cells. Pretreatment with 0.50 mg/ml (and corresponding levels of GPRP
and thrombin) resulted in a 23.55 ±0.78% inhibition, 0.75 mg/ml resulted in a 23.26 ±2.09
inhibition, and 1.0 mg/ml (and corresponding levels of GPRP and thrombin) resulted in 20.73
±5.73% inhibition. Table A- 9 in the appendix lists the specific means of each treatment.
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Figure 3-11. Effect of fibrin(ogen)/soluble fibrin (at different concentrations) on lymphocyte
transendothelial migration(measurement represents % inhibition of pretreatment versus the
negative sFn control (-/-) measurement (fluorescence).
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3. 4. 3 Effect of eACA and SFn on Lymphocyte Transendothelial Migration
Figure 3-12 is a summary of results obtained from all treatments performed compared to when
neither cell type was pretreated (-/-). When both cell types were pretreated with sFn prior to
incubation (+/+), 18.0% inhibition of migration was observed. When cells were pretreated with
sFn, and incubated with EACA (to slow fibrinolysis), 18.5% inhibition was observed. When
EACA was incubated with the cells alone, only a 0.1% inhibition was observed (n=1). Clearly,
pretreatments with sFn, in the presence or absence of EACA, were not significantly different than
one another. However, both of these pretreatments were different than EACA alone. No
additional statistical analysis was performed for this data. Specific data is listed in Table A-10 in
the appendix.
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Figure 3-12. Effect of sFn pretreatment (in the presence of eACA) on lymphocyte
transendothelial migration(measurement represents % inhibition of pretreatment versus the
negative sFn control (-/-) measurement (fluorescence).
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3. 4. 4 The Effect of Various Peptide Concentrations on Lymphocyte Transendothelial
Migration
Here, cells were pretreated with each pair of peptides, at three different concentrations (2, 4, and
8 mM), prior to observation of migration. Figure 3-13 is a summary of these treatments.
Pretreatment of both cells with sFn resulted in the maximum level of inhibition at 22.28% (n=1).
Pretreatment with P1/P3 (at 2, 4, and 8 mM) prior to exposure to sFn, resulted in 9.88, 10.82, and
7.98%, respectively. Pretreatment with P2/P4 (at 2, 4, and 8 mM) prior to exposure to sFn,
resulted in 17.5, 16.83, and 20.38%, respectively. Figure A-11 in the appendix lists all specific
measurements for each treatment.
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Figure 3-13. Effect of peptide concentration on lymphocyte transendothelial migration
(measurement represents % inhibition of pretreatment versus the negative sFn control (-/-)
measurement (fluorescence)).
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3. 5 Lymphocyte and LAK Cell Transendothelial Migration in the Presence of Soluble
Fibrin, Peptides, Fibrinogen, GPRP, and Thrombin
3. 5. 1 Lymphocyte Transendothelial Migration in the Presence of Soluble Fibrin
SFn pretreatment of one or both cell types significantly (P < 0.05) affected the number of cells
that migrated through confluent monolayers of EC grown on 8 µm inserts incubated in 24-well
plates. Figure 3-14 is a summary of the mean fluorescence units observed for each pretreatment.
Untreated cells of each type (-/-) were used as a control value of fluorescence measured (n = 6).
Furthermore, all other pretreatments were compared against this measurement in order to
calculate a percent inhibition for each treatment. Pretreatment of both cell types with sFn (+/+,
EC/lymphocytes respectively; n = 6) resulted in the fewest number of lymphocytes that migrated
through the EC (or least fluorescence observed), resulting in 29.60 ± 7.67% inhibition when
compared to the control (n = 6). Pretreatment of only EC (+/-) resulted in a 21.31 ± 7.83%
decrease of migration (n = 2), and pretreatment of lymphocytes only (-/+) resulted in a 17.87 ±
2.30% decrease of migration (n = 2). Specific data are listed in Table A-5 in the appendix.

3. 5. 2 Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of
Soluble Fibrin
Using JMP, matched pair student t-tests (α = 0.05) were performed for all possible pairs of the
four pretreatment combinations of sFn (-/-, +/+, -/+, +/-). When neither cell type was pretreated
with sFn (-/-), the mean fluorescence (migration) was significantly greater than double
pretreatment of cells with sFn (n=6). However, when only one cell type was pretreated with sFn
(+/-) and (-/+), the mean fluorescence was not found to be significantly different than either
double sFn (+/+) pretreatment or untreated cells (-/-). Details for the t-tests appear in Table A-6
in the appendix.
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Figure 3-14. Effect of soluble fibrin on lymphocyte transendothelial migration (measurement
represents % inhibition of pretreatment versus the negative sFn control (-/-) measurement
(fluorescence).
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Also using JMP, an additive model, including terms for date (6 days) and treatment (4 levels),
was fit using Standard Least Squares (Table 3-9 (A-E)). I obtained an R2 value of 0.98
Table 3-9 (A), with treatment differences explaining the vast majority of the variation within
fluorescence. The Root Mean Square Error of 12624.0 estimates the assumed common standard
deviation. The mean of response and total observations (16) are also listed.

Furthermore, the analysis of variance (ANOVA) (Table 3-9 (B)) provided an F ratio of 49.8 (P
<.0001), indicating a significant model. The model accounts for approximately 98% of variation
(from R2 value), whereas the unexplained variation accounts for the other approximate 2% of
variance.

The residuals were also examined, and were consistent with our assumption of a common
variance. There are no “extreme outliers” that need additional attention for this model (Table 3-9
(C)).

The Effect Tests Table (Table 3-9(D)) indicates that both date (DF=5) of the experiment and
pretreatment (DF=3) were found to be significant factors (P<0.0001; F Ratio=39.6 and P < .0001;
F Ratio=50.4, respectively). Day could again be a significant factor due to the use of different
reagents from day to day of experiments.

Table 3-9(E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that the LSM and mean values are the same for both

89

Table 3- 9. Statistical analysis: Lymphocyte transendothelial migration in the presence of soluble
fibrin.
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.982728
12624.02
253010.5
16

B) Analysis of Variance
Source
Model
Error
C. Total

DF
8
7
15

Sum of Squares
6.3472e+10
1115560289
6.4587e+10

Mean Square
7.9339e+9
159365756

F Ratio
49.7845
Prob > F
<.0001

C) Residual by Predicted Plot
15000

Data Residual

10000
5000
0
-5000
-10000
-15000
100000

200000

300000

400000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
5
3

DF
5
3

Sum of Squares
3.154e+10
2.408e+10

F Ratio
39.5825
50.3671

Prob > F
<.0001
<.0001

E) Least Squares Means Table
Level
(-/-)
(-/+)
(+/-)
(+/+)

Least Sq Mean
310501.00
268712.42
258686.92
221112.33

Std Error
5153.733
10307.465
10307.465
5153.733

Mean
310501
219635
209609
221112
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treatments (-/- and +/+) because they were performed all days. However, the LSM values for
both intermediates (+/- and -/+) have been adjusted in an upward (positive) direction. This is due
to fact that those days that (-/+) and (+/-) were tested, the mean fluorescence measurement tended
to be lower (respectively) than other days included.

Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 310(A) includes the specific details for each sFn pretreatment, including the lower and upper
bounds (or confidence intervals) with 95% certainty (CL Dif). Those values that are in red
correspond to significant differences in the model. Using this method, it was shown that when
neither cell was pretreated with sFn (-/-), the average fluorescence measurement was significantly
different than all other pretreatments involving sFn. Furthermore, when both cell types were
treated with sFn (+/+), the average fluorescence measurement was significantly different from the
(-/+) pretreatment mean. The intermediate treatments’ average measurements were not
significantly different than one another. Table 3-10(B) is a summary of these results.

3. 5. 3 Lymphocyte Transendothelial Migration in the Presence of Fibrinogen, GPRP, and
Thrombin
Figure 3-15 is a summary of inhibitions observed due to pretreatment of lymphocytes and EC
with those components that are combined to create sFn in vitro: fibrinogen, GPRP, and thrombin.
EC and lymphocytes that were pretreated with fibrinogen resulted in a 14.61 ± 3.79% decrease of
migration (fluorescence) through endothelial monolayers (n=2). EC and lymphocytes treated
with GPRP resulted in only a 3.99 ± 2.89% decrease of fluorescence (n=2). And when both cells
were pretreated with thrombin, the average fluorescence measurement was decreased by 5.93 ±
6.86% (n=2). The original data for each date is listed in Table A-5 in the appendix.
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Table 3-10. LSMeans Differences Tukey’s HSD Multiple Comparison Method. Those columns
in red are significant.
A) α=0.050 Q=3.31024 LSMean[i] By LSMean[j]
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(-/-)

(-/+)

(+/-)

(+/+)

(-/-)

(-/+)

(+/-)

(+/+)

0
0
0
0
-41789
11524.1
-79936
-3641
-51814
11524.1
-89962
-13667
-89389
7288.48
-113515
-65262

41788.6
11524.1
3641.02
79936.1
0
0
0
0
-10026
12624
-51814
31763.1
-47600
11524.1
-85748
-9452.5

51814.1
11524.1
13666.5
89961.6
10025.5
12624
-31763
51814.1
0
0
0
0
-37575
11524.1
-75722
572.98

89388.7
7288.48
65262
113515
47600.1
11524.1
9452.52
85747.6
37574.6
11524.1
-572.98
75722.1
0
0
0
0

B) Summary of Tukey’s test.Levels not connected by same letter are significantly different.
Level
(-/-)
(-/+)
(+/-)
(+/+)

A
B
B C
C

Least Sq Mean
310501.00
268712.42
258686.92
221112.33

92

40
35

% Inhibition

30
25
20
15
10
5
0
sfn/sfn

Fg/Fg

GPRP/GPRP

Thr/Thr

Pretreatment

Figure 3-15. Effect of soluble fibrin, fibrinogen, GPRP, and thrombin pretreatment on
lymphocyte transendothelial migration(measurement represents % inhibition of pretreatment
versus the negative sFn control (-/-) measurement (fluorescence)).
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3. 5. 4 Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of
Fibrinogen, GPRP, and Thrombin
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of interest for the
five possible pretreatment combinations (-/-, +/+, Fg/Fg, GPRP/GPRP, Thr/Thr). Individual tests
are listed in Table A- 6 in the appendix. When both cells were pretreated with sFn (+/+), the
mean fluorescence was significantly different than when neither cell was pretreated (n=6). When
neither cell type was treated with sFn (-/-), the average fluorescence was not significantly
different than all other treatments. Similarly, there were no additional significant differences
found between any of the other treatment combinations. These not-significant differences are not
surprising, given that we only have 1 DF for error for each test.

Also using JMP, an additive model, including terms for date (6 days) and treatment (5 levels),
was fit using Standard Least Squares. I obtained an R2 value of 0.98 (Table 3-11(A)), with
treatment differences explaining the vast majority of the variation within fluorescence. The Root
Mean Square Error of 11,539 estimates the assumed common standard deviation. The mean of
response and total observations (18) are also listed.

Furthermore, the ANOVA (Table 3-11(B)) provided an F ratio of 47.8 (P <.0001), indicating a
significant model. This model accounts for approximately 98% of variation (from R2 value),
whereas the unexplained variation accounts for the remaining 2%.

The residuals were also examined, and they were consistent with our assumption of a common
variance. There are no “extreme outliers” that need additional attention for this model. (Table 311(C)).
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Table 3- 11. Statistical analysis: lymphocyte transendothelial migration in the presence of
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.981749
11538.61
265537.4
18

B) Analysis of Variance
Source
Model
Error
C. Total

DF
9
8
17

Sum of Squares
5.7295e+10
1065115386
5.836e+10

Mean Square
6.3661e+9
133139423

F Ratio
47.8150
Prob > F
<.0001

C) Residual by Predicted Plot

Data Residual

10000
5000
0
-5000
-10000
100000

200000

300000

400000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
5
4

DF
5
4

Sum of Squares
3.2319e+10
2.5503e+10

F Ratio
48.5490
47.8877

Prob > F
<.0001
<.0001

E) Least Squares Means Table
Level
(-/-)
(+/+)
Fg/Fg
GPRP/GRRP
Thr/Thr

Least Sq Mean
310501.00
221112.33
262728.04
292657.79
286616.04

Std Error
4710.6161
4710.6161
9421.2322
9421.2322
9421.2322

Mean
310501
221112
247060
276989
270948
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The Effect Tests Table (Table 3-11(D)) indicates that the date (DF=5) of the experiment was
found to be a significant factor (P<0.0001; F Ratio=48.5). Pretreatment (DF=4) was also found
to be a significant factor (P < .0001; F Ratio=47.9). The use of different reagents could
contribute to the fact that day was found to be significant as discussed earlier.

Table 3-11(E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for both
treatments (-/- and +/+) because they were performed all days. However, the LSM value for all
other treatments (Fg/Fg, GPRP/GPRP, Thr/Thr) have all been adjusted in a upward (positive)
direction. This is due to fact that those days that these treatments were tested, the fluorescence
measurements tended to be lower than for the other days.
Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 312(A) includes the specific details for each sFn pretreatment, including the lower and upper
bounds (or confidence intervals) with 95% certainty (CL Dif). Those values that are in red
correspond to significant differences in the model.

Table 3-12(B) includes a summary of these results. Using this method, when both cell types were
pretreated with sFn (+/+), the average fluorescence was significantly different than all other
treatments. Furthermore, when neither cell type was pretreated (-/-), the fluorescence was not
significantly different than pretreatment with GPRP or thrombin. However, when neither cell
was pretreated was significantly different than fibrinogen pretreatment.
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Table 3-12. LSMeans Differences Tukey’s HSD multiple comparisons method. Those columns
in red are significant.
A) LSMean[i] By LSMean[j]; α=0.050; Q=3.45476;
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(-/-)

(+/+)

Fg/Fg

GPRP/GRRP

Thr/Thr

(-/-)

(+/+)

Fg/Fg GPRP/GRRP

0
0
0
0
-89389
6661.82
-112404
-66374
-47773
10533.3
-84163
-11383
-17843
10533.3
-54233
18546.7
-23885
10533.3
-60275
12504.9

89388.7
6661.82
66373.7
112404
0
0
0
0
41615.7
10533.3
5225.83
78005.6
71545.5
10533.3
35155.6
107935
65503.7
10533.3
29113.8
101894

47773
10533.3
11383.1
84162.8
-41616
10533.3
-78006
-5225.8
0
0
0
0
29929.8
11538.6
-9933.4
69792.9
23888
11538.6
-15975
63751.1

Level
(-/-)
GPRP/GRRP
Thr/Thr
Fg/Fg
(+/+)

A
A B
A B
B

Least Sq Mean
310501.00
292657.79
286616.04
262728.04
221112.33

17843.2
10533.3
-18547
54233.1
-71545
10533.3
-107935
-35156
-29930
11538.6
-69793
9933.37
0
0
0
0
-6041.7
11538.6
-45905
33821.4

Thr/Thr

23885
10533.3
-12505
60274.8
-65504
10533.3
-101894
-29114
-23888
11538.6
-63751
15975.1
6041.75
11538.6
-33821
45904.9
0
0
0
0

B)

C
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3. 5. 5 Lymphocyte Transendothelial Migration in the Presence of Peptides and Soluble
Fibrin
Figure 3-15 is a summary of effects on lymphocyte/EC migration (% inhibitions), caused by
pretreatment of peptides, prior to incubation with sFn. When cells and sFn were pretreated with
both peptides 1 and 3, respectively, resulted in only a 7.92 ± 2.2% inhibition of average
fluorescence (migration). And when cells and fibrin were pretreated with peptides 2 and 4,
respectively, resulted in a 9.03 ± 0.58% inhibition of fluorescence. Specific data are listed in
Table A-5 in the appendix.

3. 5. 6 Statistical Analysis: Lymphocyte Transendothelial Migration in the Presence of
Peptides and SFn
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of the original
data for the four possible pretreatment combinations (-/-, +/+, P1/P3, and P2/P4). When neither
cell type was pretreated with sFn (-/-), the average fluorescence was not significantly different
than the average fluorescence from when both cells were pretreated (+/+). Furthermore, when
cells were pretreated with either peptide pair, P1/P3 or P2/P4 prior to sFn, the fluorescence
measurement was not significantly different than (-/-) or (+/+) fluorescence measurements. These
not-significant results are not surprising given the low number of DF (1) for this comparison.
Details of specific t-test are listed in Figure A-6 in the appendix.

Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels),
was fit using Standard Least Squares. I obtained an R2 value of 0.99 (Table 3-13(A)), with
treatment differences explaining the vast majority of the variation within fluorescence. The Root
Mean Square Error is the assumed standard deviation.
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Figure 3-16. Effect of peptides and soluble fibrin on lymphocyte transendothelial migration
(measurement represents % inhibition of pretreatment versus the negative sFn control (-/-)
measurement (fluorescence).
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Table 3-13. Statistical analysis: lymphocyte transendothelial migration in the presence of
peptide and soluble fibrin.
A) Summary of Fit
RSquare
RSquare Adj
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.992238
0.983368
9167.846
285051.8
16

B) Analysis of Variance
Source
Model
Error
C. Total

DF
8
7
15

Sum of Squares
7.5213e+10
588345795
7.5801e+10

Mean Square
9.4016e+9
84049399

F Ratio
111.8580
Prob > F
<.0001

C) Residual by Predicted Plot

Data Residual

10000

5000

0

-5000

-10000
100000

200000

300000

400000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
5
3

DF
5
3

Sum of Squares
3.3449e+10
2.4285e+10

F Ratio
79.5938
96.3127

Prob > F
<.0001
<.0001

E) Least Squares Means Table
Level
(-/-)
(+/+)
P1/P3
P2/P4

Least Sq Mean
310501.00
221112.33
279958.29
276123.79

Std Error
3742.7574
3742.7574
7485.5149
7485.5149

Mean
310501
221112
344705
340870
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Furthermore, the ANOVA (Table 3-13(B)) provided an F ratio of 111.8 (P <.0001), indicating a
significant model. This model accounts for approximately 99% of variation (from R2 value),
whereas, the unexplained variation accounts for the other 1% of variation.

The residuals were also examined, which were consistend with our assumption of a common
variance. There are no “extreme outliers” that need additional attention for this model (Table 313(C)).

The Effect Tests Table (Table 3-13(D)) indicates that the date (DF=5) of the experiment was
found to be a significant factor (P<0.0001; F Ratio=79.6). Pretreatment (DF=3) was also found
to be a significant factor (P < .0001; F Ratio=96.3). The use of different reagents may have
contributed to the fact that day was a significant factor.

Table 3-13(E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for both
treatments (-/- and +/+) because they were performed all days. However, the LSM values for the
other treatments (P1/P3 and P2/P4)) have both been adjusted: P1/P3 in a downward (negative)
direction, and P2/P4 adjusted in an upward direction. This is due to fact that the days that these
treatments were tested, their fluorescence measurement tended to be higher and lower,
respectively, than the other days of the model.

Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 314 includes the specific details for each sFn pretreatment, including the lower and upper bounds
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Table 3-14. LSM Differences Tukey’s HSD multiple comparisons method (peptides and sFn)
A) α=0.05;Q=3.31024; LSMean[i] By LSMean[j]
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
(-/-)

(+/+)

P1/P3

P2/P4

(-/-)

(+/+)

P1/P3

P2/P4

0
0
0
0
-89389
5293.06
-106910
-71867
-30543
8369.06
-58246
-2839.1
-34377
8369.06
-62081
-6673.6

89388.7
5293.06
71867.4
106910
0
0
0
0
58846
8369.06
31142.3
86549.6
55011.5
8369.06
27307.8
82715.1

30542.7
8369.06
2839.08
58246.3
-58846
8369.06
-86550
-31142
0
0
0
0
-3834.5
9167.85
-34182
26513.3

34377.2
8369.06
6673.58
62080.8
-55011
8369.06
-82715
-27308
3834.5
9167.85
-26513
34182.3
0
0
0
0

B) Summary of Tukey’s test. Levels not connected by same letter are significantly different.
Level
(-/-)
P1/P3
P2/P4
(+/+)

A
B
B
C

Least Sq Mean
310501.00
279958.29
276123.79
221112.33

.
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(confidence intervals) with 95% certainty (CL Dif). Those values that are in red correspond to
significant differences in the model.

Using this method, it was again shown that when neither cell was pretreated with sFn (-/-), the
average fluorescence was significantly different than the other pretreatment of double
pretreatment with sFn (+/+). Furthermore, when cells were pretreated with either P1/P3 or P2/P4,
the average fluorescence was significantly different than when both cell types were treated with
sFn and than when neither was pretreated. Table 3-14(B) is a summary of these results.

3. 5. 7 IL-2 Activated LAK Cell/Lymphocyte Transendothelial Migration in the Presence of
Soluble Fibrin and Peptides
Here, lymphocytes and LAK cells (activated with IL-2) were incubated for approximately 72
hours. SFn pretreatment of one or both cell types (EC and 3 day incubated lymphocytes)
significantly affected the number of cells that migrated through confluent monolayers of EC on 8
µm inserts in 24-well plates. Untreated cells (-/-) were used as a control value of maximum
number of events measured (n=3); a separate control was performed for untreated lymphocytes
and untreated LAK cells. Figure 3-17 is a summary of means and standard deviations associated
with each of these combinations. Pretreatment of lymphocytes and EC with sFn (+/+,
EC/lymphocytes respectively; n=3) resulted in the least fluorescence observed, resulting in a
17.24 ± 0.99% inhibition when compared to its control. Pretreatment of both EC and IL-2
activated LAK cells with sFn (LAK +/+) resulted in an 12.24 ± 4.9% inhibition of fluorescence
(migration), when compared to the control including LAK cells (n=3). EC and LAK cells that
were pretreated with P1/P3 resulted in 1.85 ± 8.94% mean inhibition of migration (n=2). And
cells treated with P2/P4 resulted in a 3.19 ± 3.51% decrease of migration (n=2). Specific means
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Figure 3-17. Effect of soluble fibrin and peptides on LAK cell transendothelial migration.

104

are listed in figure A-7 in the appendix.

3. 5. 8 Statistical Analysis: LAK Cell Transendothelial Migration in the Presence of Soluble
Fibrin and Peptides
Using JMP, matched pair student t-tests (α = 0.05) were performed on all pairs of the original
data for the four possible pretreatment combinations (-/-, +/+, P1/P3, and P2/P4). When 3 day
old lymphocytes and EC were pretreated with sFn (lymph +/+), the mean fluorescence was
significantly different than when neither cell type was pretreated (lymph -/-). This combination
was performed to test the level of migration achieved by these older lymphocytes (in the absence
and presence of sFn). When both 3 day old, IL-2 incubated LAK cells and EC were pretreated
with sFn (LAK +/+), the average fluorescence was not significantly different than when neither
cell type was pretreated (LAK -/-). Furthermore, when LAK cells and EC were pretreated with
either P1/P3 or P2/P4 prior to sFn, the mean fluorescence was not significantly different than
either (LAK -/-) or (LAK +/+). These not-significant results are not surprising, given that we
only have 1 DF for error for each test. Details of t-tests are listed in Table A-8 of the appendix.

Also using JMP, an additive model, including terms for date (2 days) and treatment (4 levels),
was fit using Standard Least Squares (Figure 3-15). I obtained an R2 value of 0.94 (Table 315(A)), with treatment differences explaining the vast majority of the variation within
fluorescence. The Root Mean Square Error of 13678 estimates the assumed common standard
deviation. The mean of response and total observations (16) are also listed.

Furthermore, the ANOVA (Table 3-15(B)) provided an F ratio of 20.36 (P <.0002), indicating a
significant model. This model accounts for approximately 94% of variation, whereas unexplained
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Table 3-15. Statistical analysis: LAK cell transendothelial migration in the presence of sFn and
peptides.
A) Summary of Fit
RSquare
Root Mean Square Error
Mean of Response
Observations (or Sum Wgts)

0.946847
13677.96
338778.5
16

B) Analysis of Variance
Source
Model
Error
C. Total

DF
7
8
15

Sum of Squares
2.6661e+10
1496691733
2.8158e+10

Mean Square
3.8087e+9
187086467

F Ratio
20.3582
Prob > F
0.0002

C) Residual by Predicted Plot
20000
15000
Data Residual

10000
5000
0
-5000
-10000
-15000
-20000
250000

300000

350000

400000

Data Predicted

D) Effect Tests
Source
Date
Label

Nparm
2
5

DF
2
5

Sum of Squares
2187730589
2.5074e+10

F Ratio
5.8468
26.8044

Prob > F
0.0272
<.0001

E) Least Squares Means Table
Level
LAK (-/-)
LAK (+/+)
LAK (P1/P3)
LAK (P2/P4)
Lymph (-/-)
Lymph (+/+)

Least Sq Mean
384103.50
336453.83
375289.00
371002.75
325696.83
269705.83

Std Error
7896.971
7896.971
10066.703
10066.703
7896.971
7896.971

Mean
384104
336454
370287
366001
325697
269706
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variation accounts for the the remaining 6%.

The residuals were examined, which were consistent with our assumption of a common variance.
There are no “extreme outliers” that need additional attention for this model (Table 3-15(C)). The
Effect Tests Table (Table 3-15(D)) indicates that the date (DF=2) of the experiment was not
found to be a significant factor (P<0.0272; F Ratio=5.85). Pretreatment (DF=3) was found to be
a significant factor (P < .0001; F Ratio=26.8).

Table 3-15(E) is the Least Square Means table that was generated using this model. Furthermore,
the specific LSM value is included for each, followed by the computed standard error and the
standard mean computation. Note that both the LSM and mean are again the same for both
lymphocyte and LAK cell sFn treatments (-/- and +/+) because they were performed all days.
However, the LSM values for the other treatments (P1/P3 and P2/P4)) have both been adjusted:
P1/P3 in an upward (positive) direction. This is due to fact that the days that these treatments
were tested, fluorescence measurements tended to be lower than the other days of the model.

Using the computed LSM values, Tukey’s multiple comparison method was performed. Table 316(A) includes the details for each sFn treatment, including the lower and upper bounds
(confidence intervals) with 95% certainty (CL Dif). Those values in red correspond to significant
differences in the model. Using this method, it was shown that when neither cell was pretreated
with sFn (-/-), the average fluorescence was significantly different than all other pretreatments’
average measurements. Furthermore, when cells were pretreated with either P1/P3 or P2/P4, the
average fluorescence was significantly different than when both cell types were pretreated with
sFn, and than when neither was pretreated. Table 3-16(B) is a summary of these results.
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Table 3-16. LSM Differences Tukey’s HSD multiple comparisons method (LAK cells).
A) LSMean[i] By LSMean[j]α=0.050 Q=3.65371
Mean[i]-Mean[j]
Std Err Dif
Lower CL Dif
Upper CL Dif
LAK (-/-)

LAK (+/+)

LAK (P1/P3)

LAK (P2/P4)

Lymph (-/-)

Lymph (+/+)

LAK (-/-)

LAK
(+/+)

LAK
(P1/P3)

LAK Lymph (-/(P2/P4)
)

Lymph
(+/+)

0
0
0
0
-47650
11168
-88454
-6845.1
-8814.5
12794.6
-55562
37933.1
-13101
12794.6
-59848
33646.8
-58407
11168
-99211
-17602
-114398
11168
-155202
-73593

47649.7
11168
6845.06
88454.3
0
0
0
0
38835.2
12794.6
-7912.4
85582.7
34548.9
12794.6
-12199
81296.5
-10757
11168
-51562
30047.6
-66748
11168
-107553
-25943

8814.5
12794.6
-37933
55562.1
-38835
12794.6
-85583
7912.38
0
0
0
0
-4286.3
13678
-54261
45689
-49592
12794.6
-96340
-2844.6
-105583
12794.6
-152331
-58836

13100.8
12794.6
-33647
59848.3
-34549
12794.6
-81296
12198.6
4286.25
13678
-45689
54261.5
0
0
0
0
-45306
12794.6
-92053
1441.63
-101297
12794.6
-148044
-54549

114398
11168
73593.1
155202
66748
11168
25943.4
107553
105583
12794.6
58835.6
152331
101297
12794.6
54549.4
148044
55991
11168
15186.4
96795.6
0
0
0
0

58406.7
11168
17602.1
99211.3
10757
11168
-30048
51561.6
49592.2
12794.6
2844.62
96339.7
45305.9
12794.6
-1441.6
92053.5
0
0
0
0
-55991
11168
-96796
-15186

B) Summary of Tukey’s test. Levels not connected by same letter are significantly different.
Level
LAK (-/-)
LAK (P1/P3)
LAK (P2/P4)
LAK (+/+)
Lymph (-/-)
Lymph (+/+)

A
A B
A B C
B C
C
D

Least Sq Mean
384103.50
375289.00
371002.75
336453.83
325696.83
269705.83

.
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CHAPTER 4. SUMMARY OF RESULTS AND CONCLUSIONS
 OG labeled sFn (sFn) binds to IL-2 activated lymphocytes (LAK cells) and EC.
 SFn pretreatment inhibited lymphocyte (sign. Student’s t-test and Tukey) and LAK cell
(sign. Tukey) adherence to EC under flow conditions.
 SFn reagents (fibrinogen, GPRP, and thrombin individually) did not significantly affect
lymphocyte/LAK cell adherence to EC under flow conditions.
 P1/P3 pretreatment, prior to sFn exposure, significantly (Student’s t-test and Tukey)
restored lymphocyte and LAK cell adherence to EC.
 P2/P4 pretreatment minimally restored lymphocyte and LAK cell adherence and was not
a significant factor (Tukey).
 SFn pretreatment inhibited lymphocyte (sign. Student’s t-test and Tukey) and LAK cell
(sign. Tukey) transendothelial migration across EC (toward TCCM).
 SFn components (GPRP, and thrombin individually), did not significantly affect
(Tukey’s) lymphocyte migration. However, pretreatment with fibrinogen did
significantly affect lymphocyte migration through EC.
 Pretreatment with either peptide pair (P1/P3 or P2/P4), prior to sFn exposure,
significantly (Tukey) restored both lymphocyte and LAK cell diapedesis through EC.
 Fibrinolysis was determined to be minimal in the process of the transendothelial
migration assay.
 Tested peptide concentrations (2, 4, 8 mM) resulted in comparable levels of inhibition (of
diapedesis).
 Fibrinogen concentration (0.25, 0.50, 0.75, 1.0 mg/ml, and corresponding concentrations
of other reagents to make sFn) was found to be insignificant factor above the
concentration of 0.5 mg/ml.
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CHAPTER 5. DISCUSSION
The results from these studies confirm the first of our hypotheses that sFn inhibits lymphocyte
and LAK cell adherence to and diapedesis across endothelial monolayers.

The first aim of this study was to determine if sFn, which is elevated in the circulation of many
cancer patients, affects the ability of peripheral blood lymphocytes to adhere to endothelium in
vitro.

Initial experiments demonstrated that Oregon Green labeled sFn binds to both LAK cells and EC
in vitro. These results correspond with our previously published data that sFn also binds to
lymphocytes, monocytes, and tumor cells in vitro (Figures A-7 and A-8; Biggerstaff, 2007,
Biggerstaff, 2006).

Subsequent experimentation, involving lymphocyte/EC binding assays under flow conditions,
resulted in a significant inhibition of lymphocyte binding to EC. Maximal inhibition was
observed when both cells were pretreated with sFn prior to inclusion in assays, however
significant inhibition was also observed when only one cell type was pretreated. These results
correspond well with our previous findings that sFn also inhibits lymphocyte (Figure A-1;
Biggerstaff 2007) adherence (and cytotoxicity) to tumor cells by the same integrin mediated
mechanism. This hypothesis is further supported due to the inability of individual sFn
components (fibrinogen, GPRP, and thrombin) to significantly effected lymphocyte binding to
EC, suggesting that the entire sFn molecule intact is required for inhibition to occur.

We have previously demonstrated that the predominant lymphocyte subset which interacts with
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A375 melanoma cells is the CD8+ cytotoxic T cell (Biggerstaff, 2007). The predominant
mechanism by which T lymphocytes adhere to EC is via CD11a/CD18 (which does not bind
fibrin(ogen)) binding to EC CD54. Other leukocytes, such as monocytes, NK cells, and
neutrophils also express an additional CD54 binding beta-2 integrin, CD11b/CD18, which also
binds fibrin(ogen). Our observation that lymphocytes actually bound sFn, but do not express
CD11b/CD18, would suggest that another receptor is responsible for fibrin binding to
lymphocytes and LAK cells. Another leukocyte integrin expressed by lymphocytes, αXβ2 does
not bind to CD54, but does bind to fibrin(ogen) using the same binding motif as for CD11b. No
experiments were performed in this study to investigate the role of αXβ2 sFn/lymphocyte binding.

As discussed previously, Ugarova et al. have found particular peptide sequences corresponding to
the gamma chain on fibrin(ogen) and complementary sequences on CD11b/Cd18 (P2/P4) and
CD54 (P1/P3). In the present study, using lymphocytes as effector cells, only two of these
peptides, P1 and P3, were anticipated to affect adherence significantly. However, peptides 2 and
4 were used in this study to control for other CD11b containing leukocyte subsets which may
have remained after lymphocyte purification. As expected, lymphocyte adherence was
significantly restored with the application of appropriate peptides (P1 and P3), but not by peptides
P2 and P4. Thus, peptide blockade of either the CD54 binding site for fibrin, and the fibrin
binding site for CD54, was confirmed to be an important mechanism in lymphocyte adherence to
EC under these conditions.

Activated lymphocyte, or LAK cell, adherence to EC was similarly inhibited by sFn, confirming
our previous observations (Biggerstaff, 2007) using LAK cell adherence to tumor cells (Figure A1).
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LAK cell adherence, in the presence of sFn, was restored with pretreatment of P1/P3, but not
P2/P4.

Extrapolation of these results to the physiological setting would suggest that, in cancer patients
with elevated levels of sFn, leukocytes (lymphocytes and monocytes), EC, and circulating tumor
cells would bind sFn, resulting in the inability of lymphocytes and monocytes to adhere to, and
subsequently kill, tumor cells, resulting in enhanced metastasis. The use of fibrin blocking
peptides may represent a novel class of therapeutic agents to reduce sFn mediated
immunosuppression, and decrease metastasis in many cancers, while avoiding the negative
bleeding problems commonly associated with anticoagulant therapies, since they do not inhibit
normal blood coagulation.

Since adherence is a necessary step leading up to diapedesis through endothelium, combined with
the fact that sFn inhibits lymphocyte/LAK cell adherence, it was hypothesized that under
comparable conditions, cellular diapedesis would similarly be inhibited. We have previously
determined the optimal sFn and peptide conditions in previous studies, however since the
diapedesis was novel, we optimized the conditions of this assay. The optimal concentration for
sFn for inhibition was 0.5 mg/ml. The maximal restoration of diapedesis was seen using a 4 mM
concentration of P1 and P3, and 8 mM concentration of peptides for P2/P4. However, all assays
were subsequently performed at 4 mM to be comparable with previous studies and to
accommodate the limited amount of peptide available to our laboratory.

Using an 18-hour static transendothelial migration assay, both lymphocyte and LAK cell
diapedesis were inhibited by sFn in the same pattern observed for adherence. However, the
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actual level of inhibition was lower than for adherence. There are two reasons for this: 1)
Optimal cell number and experimental model parameters were different for binding and
transendothelial migration assays. 2) Diapedesis was performed for 18 hours, compared with 1
hour for adherence. This may have allowed for these cells to overcome effects of fibrin by the
employment of other molecular mechanisms such as fibrinolysis. To test this, we performed
assays in the presence of the plasmin inhibitor, eACA. However, no effect was observed.

Although lymphocyte diapedesis was not affected by GPRP or thrombin, some inhibition was
observed when cells were preincubated with fibrinogen, but to a significantly lower degree than
sFn. This may have been because some “immobilization” of fibrinogen occurred over the 18
hour period in a similar to a fashion reported by Ugarova, et al, although this group demonstrated
enhanced diapedesis when only EC were incubated with immobilized fibrinogen. Our previous
results confirm this effect using sFn enhancement of monocyte adherence to tumor cells, but
preincubation of both cell types with sFn resulted in pronounced inhibition. This would suggest
that in the present study immobilization of fibrinogen on both cell types, would explain the
observed inhibition. Since this study is concerned with sFn, further study of the mechanism(s) by
which immobilized fibrinogen mediates leukocyte/EC interactions is outside the scope of this
project.

SFn mediated inhibition of lymphocyte and LAK cell diapedesis was blocked by inclusion of
peptides P1/P3, clearly implicating CD54 as an important mediator of diapedesis, which is
consistent with previous literature.

In contrast to adherence assays, sFn mediated inhibition of lymphocyte and LAK cell diapedesis
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was also blocked using peptides P2/P4 to a similar degree observed for P1/P3, implicating
CD11b/CD18 in the mechanism of diapedesis. The increased incubation time, from 1 hour to 18
hours, may have allowed for upregulation of CD11b presence on lymphocytes and LAK cells.
Alternatively, the αxβ2 integrin present on lymphocytes and LAK cells (to a lesser degree than
CD11a/CD18) binds to sFn using the same sequence as CD11b. Although we did not study this
effect further, our results could possibly suggest a role fort his integrin in diapedesis but not in
initial binding. Furthermore, CD11b antigen is present on macrophages, granulocytes, natural
killer cells, and monocytes. However, it has also been reported on activated lymphocytes (LAK
cells)(Springer, 1979; Sanchez-Madrid, 1993). Therefore, this may somewhat explain how P2 and
P4 inhibited LAK cells binding to sFn, compared to lymphocytes

These results demonstrated that sFn is immunosuppressive and may be directly involved in the
etiology of metastasis. Clinically, elevated sFn levels in cancer patients may significantly reduce
the effectiveness of currently employed immunotherapies targeted to kill cancer cells in vivo.

The fibrin(ogen)-CD11b/CD18 and -CD54 axes can now be viewed as a potentially useful target
in the development of new therapeutic strategies for the treatment or prevention of inflammatory
diseases. In fact, the potential usefulness of fibrinogen as a target in inflammatory disease has
already been underscored in studies showing that the pharmacological or genetic depletion of
fibrinogen in mice can diminish the progression of arthritis (Busso, 1998; and unpublished data).

An important implication of the findings in studies using fibrinogen 390–396A (corresponding to the
active peptide sequence within P4 which inhibits fibrin binding to CD11b) mice is that effective
anti-inflammatory strategies focusing on fibrin(ogen)-leukocyte interactions could potentially be
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devised that would not necessarily compromise hemostatic function. Therefore, in principle,
inflammatory responses could be controlled at the level of hemostatic factors without increasing
the risk of bleeding or thrombotic events (Busso, 1998).

Specifically, recent immunotherapy studies (Rosenberg et al.) have shown that many patients’
tumors (generally stage 1) regress when activated LAK cells are introduced back into their
bloodstreams. This correlates with the many findings suggesting that those patients in the later
stages of disease, have elevated levels of sFn and its byproducts. We hypothesize that the reason
for observing regression in patients in primarily stage 1 of disease is due, at least in part, to
increased levels of sFn present in advanced stages of cancer.

This project addressed the role of sFn in specific lymphocyte adherence and diapedesis across
endothelium to tumors. However, it would not necessarily be expected that tumor cell crossing of
the endothelial barrier would be inhibited by sFn, since the mechanism of tumor cell
extravasation is not β2 integrin mediated. However, other adhesive mechanisms involving
integrins such as αVβ3 (which also binds fibrinogen) may be affected by sFn, but most
tumor/endothelial interactions involve preliminary lodgment in microcapillaries due to the large
size of most tumor cells. Under such conditions, downstream hemostasis, as well as tumor cells
and platelet release of cytokines such as VEGF, may cause endothelial death and partitioning,
respectively. This would allow tumor cells to escape into secondary organs by a nonspecific
extravasation through gaps in endothelium.

In summary, the results obtained in this project have demonstrated that sFn inhibits both
lymphocyte and LAK cell adherence to and diapedesis across endothelial monolayers. In the
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light of current immunotherapy protocols, elevated levels of sFn in the blood would be likely to
interact with reintroduced, activated lymphocytes as well as precoating existing vascular
endothelium. This would diminish the ability of therapeutic immune cells to adhere to blood
vessel walls and home to tumors in order to kill them. Our data have shown that this inhibition
can be blocked using specific peptides. The therapeutic use of such peptides may therefore
enhance the ability of immunotherapeutic cells to reach their targets, resulting in decreased
metastasis and possibly enhancing the natural immune response to tumors.

Together with our previous work, the data obtained in this project suggests novel mechanisms for
the growth, progression, and treatment of certain cancers in the future. To this end, future work
will concentrate on further defining the cellular mechanisms by which sFn, and its counterparts,
influence cancer biology. These include experimental animal models to test the efficacy of
potential peptide therapies, as well as studies investigating sFn mediated effects on cell signaling
and receptor expression, directed towards a better understanding of the role of the immune
response in cancer and other inflammatory diseases.
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Figure A-1. Inhibition of lymphocyte adherence to tumor cells by sFn. Calcein AM labeled PBL
were incubated with A375 cells after pre-treatment of A375 and/or PBL with RPMI or sFn prior
to assay. sFn pre-treatment of cell type alone resulted in decreased adherence (+/-, -/+; P<0.05;
n=3). Maximal inhibition occurred when lymphocytes or LAK cells and tumor cells (+/+) were
treated with sFn (P<0.05 compared to single treatment; n=3)(Biggerstaff, 2007).
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Figure A-2. Sfn inhibition of lymphocyte cytotoxicity against tumor cells. Calcein AM labeled
PBL incubated with A375 cells after pre-treatment of A375 with or without sFn and pre-treatment
of PBL with or without sFn prior to assay. sFn pre-treatment of either cell type alone resulted in
decreased cytotoxicity (+/-, -/+; P<0.05; n=3). Maximal inhibition of PBL and LAK cell
cytotoxic activity occurred when both cell types were treated with sFn (+/+; P<0.05 compared to
single treatment; n=3). Pre-incubation of lymphocytes and tumor cells with recalcified plasma (+
GPRP-NH2) also significantly (P < 0.05 compared to untreated; n=3) inhibited lymphocyte
cytotoxicity (Biggerstaff, 2006).
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Figure A-3. Effect of specific blocking peptides designated P1 (binds to CD54) and P2 (binds to
αMβ2) on sFn inhibition of monocyte/tumor cell adherence under flow conditions. (from left to
right): sFn pre-treatment of monocytes and A375 cells (n=25) significantly (P < 0.01 compared
to untreated control; n=30) inhibited monocyte adherence. Pretreatment of cells with P1 and P2
restored cell adherence to levels not significantly different to that of the untreated control (P<0.05
to fibrin (n=10); P>0.05 to control). Pre-treatment of tumor cells with P1 and monocytes with sFn
or tumor cells with sFn and monocytes with P2 inhibited adherence to a similar level to that of
sFn treatment of both cells (P>0.05 to fibrin; n=5 in each case). Pretreatment of effector and
tumor cells with fibrinogen (Fg), thrombin or GPRP did not significantly inhibit adherence (P >
0.05 compared to untreated cells; n=5)(Biggerstaff, 2006).
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Figure A-4. Effect of specific blocking peptides designated P3 (binds CD54 binding site on sFn)
and P4 (binds to αMβ2 binding site on sFn) on sFn inhibition of monocyte/tumor cell adherence
under flow conditions. (from left to right): sFn treatment of monocytes and A375 cells (n=25)
significantly (P < 0.01 compared to untreated control; n=10) inhibited cell adherence.
Pretreatment of sFn with P3 and P4 restored cell adherence to levels not significantly different to
the untreated control (P<0.05 to fibrin; n=5; P>0.05 to control). Pre-treatment of tumor cells
and/or monocytes with either P3+P4, P3 alone or P4 alone were not inhibitory (P > 0.05; n=5 in
each case, compared to untreated control)(Biggerstaff, 2006).
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Figure A-5. Effect of monoclonal anti-αLβ2, -αMβ2 and CD54 on monocyte adherence to tumor
cells under flow conditions in the presence or absence of sFn. Anti-αLβ2 inhibited monocyte
adherence to untreated cells (P <0.05; n=3), but was significantly (P<0.01 compared to non-sFn
treated cells; n=3) less effective in blocking monocyte binding to sFn pre-treated tumor cells.
Conversely, anti-αMβ2 inhibited monocyte adherence to sFn pre-treated tumor cells to a
significantly (P<0.01) greater extent than to untreated tumor cells. Anti-CD54 inhibited monocyte
adherence to untreated tumor cells by over 50%, and by over 80% when tumor cells were preincubated with sFn. Isotypic control IgGs or an irrelevant monoclonal antibody (CD4) did not
affect monocyte adherence (Biggerstaff, 2006).
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Figure A-6. Oregon Green Labeled Soluble Fibrin on A375 Melanoma Cells and Monocytes.
Oregon Green labeled fibrinogen (0.5 mg/ml; Molecular Probes, Eugene, OR) was treated with
thrombin (1.25 U) in the presence of 4 mM GPRP-NH2 to produce fluorescently labeled sFn.
A375 cells were incubated with labeled sFn for 20 min in a Bioptechs FCS2 enclosed stage
incubator. The residual sFn was washed away by perfusion and the cells were imaged on an
Olympus BX61 fluorescence microscope equipped with a long pass 535 nm dichroic filter.
Considerable binding of sFn was observed. A is a representative image showing tumor cell sFn
binding. In contrast, little or no binding was observed when cells were pre-incubated with
peptides P1 + P2 (B), or sFn with P3 + P4 (C). Similarly, sFn bound readily to monocytes (D),
but was inhibited when cells were pre-incubated with P1 + P2 (E), or sFn was pre-treated with P3
+ P4 (F) (Biggerstaff, 2006)
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A

B

C

D

Figure A-7. Oregon Green labeled sFn binding to lymphocytes and tumor cells. Considerable
binding of sFn was observed with both cell types. A) OG labeled sFn on lymphocytes, B)
lymphocytes without OG sFn, C) A375 cells with OG sFn, D) A375 cell without OG
sFn.(Biggerstaff, 2007).
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Figure A-8. Effect of perfusion flow rate on monocyte adherence to tumor cells. Monocytes (1
x106/ml) were perfused across a monolayer of A375 cells attached to a coverslip in a perfusion
stage incubator for 1 h at 370C, and non-adherent cells were washed off by perfusion to waste for
10 min. Monocyte adherence was maximal at a flow rate of 0.5 ml/min, and linearly decreased as
the flow rate was increased to 1, 1.5, and 2 ml/min. (Biggerstaff, 2007).
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Figure A-9. Effect of sFn on monocyte adherence to tumor cells. Calcein AM labeled PBM
incubated with A375 cells after pre-treatment of A375 and/or PBM with RPMI or sFn prior to
assay. sFn pre-treatment of tumor cells significantly increased adherence to untreated A375 cells
compared to the untreated control (P < 0.01: n=3). Preincubation of monocytes also marginally
increased adherence to untreated A375 cells (P< 0.05: n=3) compared to the untreated control,
but to a significantly lower degree than with sFn treated A375 cells (P < 0.01 compared to
monocyte sFn). sFn pre-treatment of both effector and target cells resulted in a significant
inhibition of adherence (P<0.05: n=3) compared to the untreated control.(Biggerstaff, 2006).

139

Figure A-10. Effect of sFn pre-treatment on monocyte cytotoxicity against tumor cells. Calcein
AM labeled PBM incubated with A375 cells after pre-treatment of A375 with or without sFn and
pre-treatment of PBM with or without sFn prior to assay. sFn pre-treatment of monocytes was
slightly inhibitory (P <0.05 compared to untreated control; n=3). Significantly greater inhibition
was observed when A375 cells were sFn pre-treated (P <0.01 compared to untreated and to
monocyte treated cells; n =3). Maximal inhibition of PBM cytotoxic activity occurred when both
cell types were treated with sFn (P<0.01 compared to untreated, monocyte treated or A375
treated cells: n=3).(Biggerstaff, 2006)
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Table A- 1. Lymphocyte adherence to endothelial cells under flow conditions (measured in fluorescent pixels).

2/8/2007
2/15/2007
2/18/2007
2/22/2007
2/24/2007
2/27/2007
2/28/2007
3/1/2007
3/2/2007
3/6/2007
3/8/2007
3/10/2007
3/28/2007
3/30/2007
4/2/2007
Mean
St Dev

(-/-)
3519
3453
3497
3811
4658
4094
4833
5171
3586
4359
3889
3002
3220
3678
3192
3864.13
639.36

(+/+)
1131
1841
1428
2001
1867
2043
1564
1465
1433
2779
1470
1272
1733
2214
1938
1745.27
421.76

(-/+)
.
.
.

(+/-)
.
2382
2508

3050
3038
.
.
.
.
.
.
.
.
2374
.
2820.67
386.87

.
.
.
.
.
.
.
.
.
.
2578
.
2489.33
99.32

P1/P3
.
.
.
.
.
.
3681
3545
2694
.
.
.
.
.
.
3306.67
534.92

P2/P4
.
.
.
.
.
.
.
.
.
.

Fg/Fg
.
.
.
.
.
3599
.
.
.
3773

1721
1491
2183
.
.
1798.33
352.42

.
.
.
.
3354
3575.33
210.50

GPRP/GPRP
.
.
.
.
.
4021
.
.
.
3992
.
.
.
.
3028
3680.33
565.12

Thr/Thr
.
.
.
.
.
4167
.
.
.
4185
.
.
.
.
2876
3742.67
750.61
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Table A-2. Matched pair t-tests for lymphocyte binding to endothelial cells under flow
conditions.

Comparison
Section 3.3.2
(+/+) vs (-/-)
(-/+) vs (-/-)
(+/-) vs (-/-)
(-/+) vs (+/+)
(+/-) vs (+/+)
Section 3.3.4
(Fg/Fg) vs (-/-)
(GPRP/GPRP) vs (-/-)
(Thr/Thr) vs (-/-)
(Fg/Fg) vs (+/+)
(GPRP/GPRP) vs
(+/+)
(Thr/Thr) vs (+/+)
Section 3.3.6
(-/-) vs (P1/P3)
(+/+) vs (P1/P3)
(+/+) vs (P2/P4)
(P2/P4) vs (-/-)

n

Mean Diff

Std Error
for Diff

t

two-sided
p-value

15
3
3
3
3

-2118.80
-1228.40
-1053.30
-793.07
-661.53

180.42
250.82
33.13
318.57
215.08

-11.74
-4.90
-31.79
2.49
3.08

< 0.0001
0.039
0.001
0.131
0.091

3
3
3
3
3

-306.33
-201.33
-139.00
-1322.00
-1427.00

235.64
86.70
113.65
168.91
277.78

-1.30
-2.32
-1.22
7.83
5.14

0.323
0.053
0.346
0.016
0.036

3

-1489.33

344.90

4.32

0.050

3
3
3
3

-1223.80
-1819.10
-306.33
-1571.90

214.89
279.27
72.23
327.93

5.69
-6.51
-4.24
-4.79

0.029
0.023
0.051
0.041
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Table A-3.LAK cell adherence to endothelial cells under flow conditions (measured in
fluorescent pixels.

3/22/2007
6/20/2007
Mean
St Dev

(-/-)
5551.8
5233
5392.4
225.43

(+/+)
2941.8
3101.4
3021.6
112.85

P1/P3
3914
4148.4
4031.2
165.75

P2/P4
3310
3469.2
3389.6
112.57
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Table A-4. Matched pair t-tests for LAK cell adherence to endothelial cells under flow
conditions.

Comparison
Section 3.3.8
(+/+) vs (-/-)
(P1/P3) vs (-/-)
(P1/P3) vs (+/+)
(P2/P4) vs (+/+)
(P2/P4) vs (-/-)
(P1/P3) vs
(P2/P4)

n

Mean
Diff
2
2
2
2
2
2

-2370.80
-1361.20
-1009.60
-368.00
-2002.80
-641.60

Std Error for
Diff
239.20
276.60
37.40
0.20
239.00
37.60

t
-9.91
-4.92
26.99
1840.00
-8.38
-17.06

two-sided
p-value
0.064
0.128
0.024
<0.0001
0.076
0.037
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Table A-5. Lymphocyte transendothelial migration in the presence of all reagents (measured in
fluorescence units).

DATE
4/4/07
4/11/07
4/14/07
4/18/07
4/20/07
4/24/07
Mean
St Dev

neg/neg
452516.5
444845.50
416655.5
487573
514075.5
532001.5
474611.25
44163.61

DATE
4/4/07
4/11/07
4/14/07
4/18/07
4/20/07
4/24/07
Mean
St Dev

DATE
4/4/07
4/11/07
4/14/07
4/18/07
4/20/07
4/24/07
Mean
St Dev

sfn/sfn
352012.5
340870.5
338311
411093
441411
427637.5
385222.5833
46682.24

neg/sfn
396175
404759

sfn/neg
374956.5
405926.5

400467
6069.80

390441.5
21899.10

TOTAL
537489.5
575453.5
513131.5
563522.5
585990.5
595144.5
561788.6667
31132.12

Fg/Fg

GPRP/GPRP

Thr/Thr

369434
451225

411335
469183.5

413702
454733

410329.5
57834.97

440259.25
40905.07

434217.5
29013.30

P1/P3

P2/P4

491896
493970
492933
1466.54

484068.5
494128.5
489098.5
7113.49

TC/CM
163610
198054.5
143557.5
182982.5
165846
130611
164110.25
24723.48
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Table A-6. Matched pair t-tests for lymphocyte transendothelial migration results.

Comparison
Section 3.5.2
(+/+) vs (-/-)
(-/+) vs (-/-)
(+/-) vs (-/-)
(-/+) vs (+/+)
(+/-) vs (+/+)
(+/-) vs (-/+)
Section 3.5.4
(Fg/Fg) vs. (-/-)
(GPRP/GPRP) vs
(-/-)
(Thr/Thr) vs (-/-)
(Fg/Fg) vs (+/+)
(GPRP/GPRP) vs
(+/+)
(Thr/Thr) vs (+/+)
Section 3.5.6
(P1/P3) vs (-/-)
(P1/P3) vs (+/+)
(P2/P4) vs (+/+)
(P2/P4) vs (-/-)
(P2/P4) vs (P1/P3)

Std Error
for
Difference

n

Mean
Difference

two-sided pvalue

6
2
2
2
2
2

-89389
-48214
-58240
-54025
-44000
-10026

6134
8127.5
19320
9863
21056
11193

-14.57
-5.93
-3.01
5.48
2.09
-0.9

<0.0001
0.106
0.204
0.115
0.284
0.535

2

-41785

5437

-7.69

0.082

2
2
2

-11855
-17897
-35628

6535
14943
4505

-1.81
-1.2
7.91

0.321
0.443
0.08

2
2

-65557
-59515

7467
15875

8.78
3.75

0.072
0.166

2
2
2
2
2

-30106
-58408
-54574
-33940
-3835

7926
7924
11917
3933
3993

-3.8
7.37
4.58
-8.63
-0.96

0.164
0.086
0.137
0.073
0.513

t
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Table A-7. LAK cell transendothelial migration results (measured in fluorescence units).

DATE
5/17/07
5/26/07
5/30/07

Lymph
(-/-)
502584.5
444973.5
479627

LAK (-/)
552568
504168
545669

Lymph
(+/+)
444907
390045.5
424259.5

LAK
(+/+)
485738.5
478595
495122.5

LAK
(P1/P3)

LAK
(P2/P4)

520158.5
513054.5

501627
523013.5

TC/CM
157456
146055.5
146583

TOTAL
547261
538398
537056.5
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Table A-8. Matched pair t-tests for 72 hour incubated LAK cell and lymphocyte transendothelial
migration assays.

Comparison
Section 3.5.7
Lymph (+/+) vs Lymph (-/-)
LAK (-/-) vs Lymph (-/-)
LAK (+/+) vs Lymph (+/+)
LAK (+/+) vs LAK (-/-)
LAK (P1/P3) vs LAK (-/-)
LAK (P1/P3) vs LAK (+/+)
LAK (P2/P4) vs LAK (-/-)
LAK (P2/P4) vs LAK (+/+)
LAK (P2/P4) vs LAK (P1/P3)

Mean
Difference

n
3
3
3
3
2
2
2
2
2

-55991
-58406
-66748
-47650
-8312
-29748
-12598
-25462
-4286

Std Error
for
Difference
853
4652
13927
11997.5
24303
11816
10057
2430
14245

t
-65.64
12.56
4.79
-3.97
-0.34
2.52
-1.25
10.48
-0.30

two-sided
p-value
0.0002
0.0063
0.0409
0.0579
0.7902
0.2407
0.4289
0.0606
0.8139
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Table A-9. Lymphocyte transendothelial migration in the presence of various sFn concentrations
(measured in fluorescence units).

DATE
6/14/07
6/22/07

(-/-)
511695
514827

0.25 mg/ml
450246
480156

0.5 mg/ml
434956
429400

0.75 mg/ml
439015
427139

1.0 mg/ml
429014
455710

TCCM
179103
151050

TOTAL
610593
587498

Mean

513261

465201

432178

433077

442362

165076.5

599045.5

18876.92

19836.47

16330.63

St Dev

2214.66

21149.56

3928.69

8397.60
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Table A-10. Lymphocyte transendothelial migration in the presence of eACA (measured in
fluorescence units).

DATE
4/1/07

(-/-)
487958

(+/+)
429495

EACA (-/-)
487637

EACA (+/+)
427880

TC/CM
156708.5

RPMI
69617

TOTAL
590753
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Table A-11. Lymphocyte transendothelial migration in the presence of various peptide
concentrations (measured in fluorescence units).
DATE

neg/neg

sfn/sfn

P1/P3
(2mM)

P1/3
(4mM)

P1/3
(8mM)

P2/P4
(2mM)

P2/4
(4mM)

P2/4
(8mM)

TCCM

TOTAL

5/7/07

590156

501333

550781

547011

558328

521786

523044

508926

191510.5

613746
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